var title_f27_0_27648="Technet RBC scan divertic bleed";
var content_f27_0_27648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Technetium labeled red blood cell scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A technetium labeled red blood cell scan from a 63-year-old patient with a 24-hour history of bright red blood per rectum reveals increased activity in the distal transverse colon near the splenic flexure (arrow) which progresses toward the descending colon and sigmoid colon by termination of the examination at one hour. These findings are consistent with bleeding from a source in the distal transverse colon near the splenic flexure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27648=[""].join("\n");
var outline_f27_0_27648=null;
var title_f27_0_27649="Lyme disease prevention";
var content_f27_0_27649=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Lyme disease prevention (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/0/27649/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27649/contributors\" id=\"au2858\">",
"       Linden Hu, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/0/27649/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27649/contributors\" id=\"se1447\">",
"       Allen C Steere, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/0/27649/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27649/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/0/27649?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      LYME DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Several measures may help prevent tick bites and tick-borne illnesses, such as Lyme disease. These include personal precautions, such as wearing long pants and long-sleeved shirts, wearing tick repellent, and also making changes to areas in your yard where deer ticks are likely to live.",
"    </p>",
"    <p>",
"     The diagnosis and treatment of Lyme disease are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"      \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"      \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about Lyme disease is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"      \"Prevention of Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"      \"Evaluation of a tick bite for possible Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"      \"Epidemiology of Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"      \"Clinical manifestations of Lyme disease in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link\">",
"      \"Lyme disease: Clinical manifestations in children\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"      \"Diagnosis of Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"      \"Treatment of Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"      \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PERSONAL PRECAUTIONS",
"     </span>",
"    </p>",
"    <p>",
"     You can take precautions to prevent ticks from attaching to your skin if you know that you will be spending time in tick-infested areas where Lyme disease",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     other tick-borne illnesses are common.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Wear protective clothing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ticks can be kept away from the skin by wearing long-sleeved shirts and long trousers tucked into socks. Wearing light-colored clothing will make it easier to spot ticks on clothing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Use a tick repellent or tick-killing product",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several different commercially available products repel or kill ticks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      DEET",
"     </span>",
"     &nbsp;&mdash;&nbsp;The repellent that is most commonly used against ticks in the United States is DEET (N,N-diethyl-3-methylbenzamide). Products with 10 to 35 percent DEET are adequate in most circumstances and are effective for approximately two hours.",
"    </p>",
"    <p>",
"     As the concentration of DEET increases, the duration of activity increases; a concentration of about 24 percent provides an average of five hours of protection. Because DEET can wash off with swimming and perspiration, it may be necessary to reapply the product periodically. DEET can cause hives and blister-like lesions in some adults and children.",
"    </p>",
"    <p>",
"     It is important to talk with a healthcare provider about guidelines for using DEET on children; products with more than 30 percent DEET should not be used. Small children exposed to large amounts of DEET have rarely experienced seizures. Furthermore, DEET should be stored safely out of the reach of children; small children who swallow DEET may experience seizures, coma, and even death.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Picardin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Picaridin is another tick repellent that is available without a prescription in the United States, as a 7 or 15 percent solution (as Cutter Advanced&trade; and Cutter Advanced Sport&trade;, respectively). This agent has been successfully used for years as a tick repellent at even higher concentrations in Europe and Australia. The United States Centers for Disease Control and Prevention currently recommends picaridin as an alternative to DEET.",
"    </p>",
"    <p>",
"     The manufacturer recommends applying picardin every three to four hours. No toxicity in humans has been reported, although liver toxicity has been reported in rats at very high doses. Unlike DEET, picaridin does not usually cause side effects. Picaridin is odorless, non-sticky, and non-greasy; it also does not irritate skin, stain fabrics, or degrade plastics.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Permethrin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Permethrin (sold as Permanone&reg;) is a pesticide that kills ticks and mites. It can be applied to clothes, tents, and bed netting (but not directly to skin) and is effective in reducing the risk of tick bites. Permethrin does not appear to be harmful to humans, although it occasionally causes swelling and redness of the skin. Permethrin can be applied to clothing by mixing a premeasured amount of the product with water and immersing clothing in this solution for three to four hours and allowing it to dry. It can also be sprayed directly onto clothing and allowed to dry. The tick-killing properties of permethrin can last through multiple washings.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Other products",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although citronella may repel other insects, it probably does not repel ticks. Avon's Skin-So-Soft&reg; does",
"     <strong>",
"      not",
"     </strong>",
"     repel ticks and should not be used for this purpose.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Inspect your clothes and skin",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is important to develop a habit of inspecting the skin (and a child's or significant other's skin) for ticks when coming in from the outdoors. This inspection should include areas where ticks most often bite, including the armpits, groin, backs of the knees, belt line, and the scalp. Showering or bathing may help you to detect ticks and wash off ticks that are not yet attached to your skin. Removing ticks within 36 hours makes transmission of the bacteria that causes Lyme disease very unlikely.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      CHANGES TO YOUR ENVIRONMENT",
"     </span>",
"    </p>",
"    <p>",
"     Making changes in the area where you live can reduce the chances of being exposed to ticks outdoors, although personal precautions are still essential after these changes are made.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Install a tall fence &mdash; A tall fence that keeps deer (a carrier of ticks) out of the yard can reduce the number of ticks in an outdoor area.",
"      </li>",
"      <li>",
"       Cleaning forest borders and trimming lawns &mdash; Mice tend to live in areas that border forests. Cleaning these areas and laying down a 36-inch (approximately one meter) wide border of wood chips can decrease the number of ticks on a lawn. Keeping the lawn well-trimmed and improving exposure to the sun will discourage ticks from residing in grass.",
"      </li>",
"      <li>",
"       Treating residential property with tick-killing products &mdash; Treating one's property with products that kill ticks can also reduce exposure. These products include diazinon, chlorpyrifos (sold as Dursban&reg;), and carbaryl (sold as Sevin&reg;). These products should be applied to stone walls and areas that border forests; they do not need to be applied to open lawns because ticks dry out rapidly in closely cut, sun-drenched lawns.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Placing permethrin-soaked cotton balls in cardboard tubes outside for white-footed mice (the most common carrier of Ixodes ticks) to use as nesting material may reduce the tick population; ticks feeding on these mice are killed by exposure to permethrin. However, studies have shown conflicting results of the effect of these measures on tick populations [",
"     <a class=\"abstract\" href=\"UTD.htm?27/0/27649/abstract/1\">",
"      1",
"     </a>",
"     ]. A commercial preparation based on this concept is available by the trade name Damminix Tick Tubes&reg;.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      LYME DISEASE VACCINE",
"     </span>",
"    </p>",
"    <p>",
"     A vaccine was previously available to prevent infection with B. burgdorferi. However, it is no longer available.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784798339\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3704292\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/2/22562?source=see_link\">",
"      Patient information: Rocky Mountain spotted fever (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3704319\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"      Lyme carditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"      Prevention of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"      Treatment of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/lymedisease.html\">",
"      www.nlm.nih.gov/medlineplus/lymedisease.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/lymeDisease/\">",
"      www3.niaid.nih.gov/topics/lymeDisease/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A review of Chronic Lyme Disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/topics/lymeDisease/understanding/Pages/chronic.aspx\">",
"      www.niaid.nih.gov/topics/lymeDisease/understanding/Pages/chronic.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncidod/dvbid/lyme/\">",
"      www.cdc.gov/ncidod/dvbid/lyme/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lyme Disease Foundation, Inc.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aldf.com/faq.shtml\">",
"      www.aldf.com/faq.shtml",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?27/0/27649/abstract/2-5\">",
"      2-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/0/27649?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27649/abstract/1\">",
"      Piesman J, Eisen L. Prevention of tick-borne diseases. Annu Rev Entomol 2008; 53:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27649/abstract/2\">",
"      Hayes EB, Piesman J. How can we prevent Lyme disease? N Engl J Med 2003; 348:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27649/abstract/3\">",
"      Clark RP, Hu LT. Prevention of lyme disease and other tick-borne infections. Infect Dis Clin North Am 2008; 22:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27649/abstract/4\">",
"      Poland GA. Prevention of Lyme disease: a review of the evidence. Mayo Clin Proc 2001; 76:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27649/abstract/5\">",
"      V&aacute;zquez M, Muehlenbein C, Cartter M, et al. Effectiveness of personal protective measures to prevent Lyme disease. Emerg Infect Dis 2008; 14:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_0_27649=[""].join("\n");
var outline_f27_0_27649=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           LYME DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PERSONAL PRECAUTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           CHANGES TO YOUR ENVIRONMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           LYME DISEASE VACCINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_0_27650="CDC length for age boys 0 to 36 months";
var content_f27_0_27650=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Length-for-age percentiles, boys, birth to 36 months, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 675px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27650=[""].join("\n");
var outline_f27_0_27650=null;
var title_f27_0_27651="Woods corkscrew maneuver";
var content_f27_0_27651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Wood's corkscrew maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The posterior shoulder is rotated counterclockwise until (B) it becomes anterior. The anterior shoulder rotates out from under the symphysis pubis and descends during this process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27651=[""].join("\n");
var outline_f27_0_27651=null;
var title_f27_0_27652="Goserelin: Patient drug information";
var content_f27_0_27652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Goserelin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     see \"Goserelin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zoladex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zoladex&reg;;",
"     </li>",
"     <li>",
"      Zoladex&reg; LA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691687",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat uterine bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702216",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to goserelin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Disease signs may get worse before getting better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More bone pain, blood in urine, and trouble passing urine. Most often gets better 1 to 2 weeks after care has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698960",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More bone pain after 2 to 4 weeks of care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11209 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27652=[""].join("\n");
var outline_f27_0_27652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177201\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177202\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013801\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013800\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013805\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013806\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013808\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013803\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013804\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013810\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=related_link\">",
"      Goserelin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_0_27653="Massive unilateral edema PA";
var content_f27_0_27653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unilateral pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unilateral pulmonary edema from massive pulmonary embolism involving the contralateral pulmonary artery. Chest radiograph shows a large opacity involving most of the right lung. Oligemia of the left lung is explained by a large central embolus, proven at autopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27653=[""].join("\n");
var outline_f27_0_27653=null;
var title_f27_0_27654="Erythrodermic psoriasis";
var content_f27_0_27654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Erythrodermic psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythrodermic psoriasis may be acute or chronic. It is characterized by generalized erythema and scaling from head to toe. Patients are at high risk for complications related to loss of adequate barrier protection such as infection (including sepsis) and electrolyte abnormalities secondary to fluid loss.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27654=[""].join("\n");
var outline_f27_0_27654=null;
var title_f27_0_27655="Endoscopic management of pseudocysts of the pancreas: Technique";
var content_f27_0_27655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic management of pseudocysts of the pancreas: Technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27655/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27655/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27655/contributors\">",
"     Raj J Shah, MD, FASGE, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27655/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27655/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27655/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27655/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/0/27655/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H42782401\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic drainage has become the procedure of choice in the management of most patients with pseudocysts of the pancreas, although there are a number of issues that should be considered and evaluated prior to implementation of this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The techniques of the two major approaches to endoscopic management of pancreatic pseudocysts, transmural puncture and transpapillary stent placement will be reviewed here. The efficacy and complications of these procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=see_link\">",
"     \"Endoscopic management of pseudocysts of the pancreas: Efficacy and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782409\">",
"    <span class=\"h1\">",
"     CHOICE OF PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of endoscopic procedure for drainage varies with the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/1\">",
"     1",
"    </a>",
"    ]. However, endoscopic drainage should not be considered if there is uncertainty regarding the presence of a pancreatic cystic neoplasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link\">",
"     \"Pancreatic cystic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We attempt transmural puncture in patients who have large, symptomatic pseudocysts compressing the stomach or duodenum when there is close apposition of the pseudocyst to the bowel lumen seen on CT scan. In addition, transmural puncture is the only feasible technique of endoscopic drainage in patients who have complete ductal obstruction, since transpapillary stent placement is not possible. Endoscopic ultrasound is the preferred method to localize and direct pseudocyst drainage in the absence of an endoscopically visible bulge and is often used for all pseudocysts at centers where EUS expertise is available [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with relatively small pseudocysts in communication with the main pancreatic duct are considered good candidates for transpapillary stent placement as initial therapy. This technique reduces the incidence of bleeding, but may carry an increased risk of infection compared with endoscopic transmural drainage, especially if the pseudocyst contains debris.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782417\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to drainage, blood for type and screen and surgical backup should be available. In addition, all patients are given preprocedural broad-spectrum prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients should fast after midnight the morning of the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782425\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC TRANSMURAL DRAINAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal site of puncture has been traditionally identified solely from the evaluation of an endoscopically visible bulge. However, we believe it is safer to use either endoscopic ultrasonography (EUS) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/2\">",
"     2",
"    </a>",
"    ] or endoscopic needle localization (ENL) to guide the creation of the cystenterostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/4\">",
"     4",
"    </a>",
"    ]. If uncertainty exists as to whether a pancreatic cystic neoplasm is present, we suggest pre-drainage EUS-guided fine needle aspiration for fluid analysis and cytology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link\">",
"     \"Pancreatic cystic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782433\">",
"    <span class=\"h2\">",
"     Endoscopic needle localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic needle localization can be carried out using either a diathermic puncture technique or a Seldinger technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782441\">",
"    <span class=\"h3\">",
"     Diathermic puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A precurved biliary aspiration needle designed for performing cytologic sampling during endoscopic retrograde cholangiopancreatography (ERCP) (HBAN22, Cook Endoscopy, Winston-Salem, NC) may be used or the Cystotome (Cook Endoscopy, Inc. Winston-Salem, NC).The former is a 7 Fr catheter with a metal ball tip that contains a retractable needle that projects 8 mm when extended. It is important that the side-viewing duodenoscope be maneuvered so that the puncture can be directed perpendicular to the area of maximal bulging.",
"   </p>",
"   <p>",
"    Following needle insertion, identification of the optimal site for puncture requires probing with repeated injections of small amounts of radiocontrast. If the pseudocyst lumen has not been entered, contrast will be seen extravasating into the gastric or duodenal wall or retroperitoneal space. When free flow of contrast into the pseudocyst cavity is noted, aspiration is performed to see whether clear fluid enters the catheter.",
"   </p>",
"   <p>",
"    Return of bloody fluid may represent either blood within the pseudocyst from a pseudoaneurysm, or puncture of a blood vessel in the wall, which, in the setting of unrecognized portal or splenic vein thrombosis, may be a varix. If it is unclear which of the two has been encountered, a second site may be selected, with repeat aspiration. If bloody pseudocyst fluid is confirmed, we do not proceed with diathermic puncture, but reevaluate the patient for evidence of portal hypertension or pseudoaneurysm formation and consider EUS to assist in puncture localization and to evaluate for the presence of perigastric varices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upon aspiration of clear, nonbloody fluid, a sample may be sent for Gram stain and culture if infection is suspected. Without changing needle position, additional full-strength radiocontrast is injected under fluoroscopic guidance in an attempt to partially outline the pseudocyst. Usually no more than 4 or 5 mL of contrast is required and care is taken not to over-inject, which may lead to increased wall tension and leakage.",
"   </p>",
"   <p>",
"    In an early report of 30 cases, no complications were encountered using endoscopic needle localization (ENL) prior to drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/4\">",
"     4",
"    </a>",
"    ]. For ENL, it may be preferred to puncture pseudocysts in the duodenum due to greater instrument stability, a thinner wall, and limited data that suggest duodenal puncture may be safer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apart from unsuspected perigastric varices, endoscopic needle localization in the presence of an endoscopically visible bulge provides an adequate safety margin for cystenterostomy if cautious probing of the puncture site is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782448\">",
"    <span class=\"h3\">",
"     Seldinger technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to diathermic puncture has been described for creation of the cystenterostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/7\">",
"     7",
"    </a>",
"    ]. A non-randomized study of 94 patients compared needle-knife diathermic entry to the Seldinger technique without electrocautery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/7\">",
"     7",
"    </a>",
"    ]. The Seldinger technique involved the use of a 19 or 18 gauge needle (Cook Endoscopy, Inc, Winston-Salem, NC) to perform cyst puncture. The 18 gauge needle permitted threading of a 0.035 inch guidewire into the cavity in a one-step procedure. The 19 gauge needle permitted threading of a 0.018 inch guidewire followed by exchange for a 5 Fr catheter through which the 0.035 inch guidewire was threaded. However, puncturing the duodenal wall may be difficult or not possible using these longer needles.",
"   </p>",
"   <p>",
"    Tract dilation with an 8 mm balloon preceded stent placement. The Seldinger technique and the needle-knife technique had comparable rates of successful entry (95 and 92 percent, respectively) but a trend toward lower complications of bleeding and perforation was observed with the Seldinger technique (16 versus 7 percent). However, it is the authors' experience that gastric wall thickness often does not permit entry of the cavity for tract dilation without minimal diathermic application with the needle-knife.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782455\">",
"    <span class=\"h2\">",
"     Endoscopic ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) permits direct visualization of the pseudocyst cavity, an assessment of the pseudocyst wall, and evaluation of the distance of the cyst from the intestinal lumen. Early experience was limited by the relatively small working channel of echoendoscopes, necessitating smaller-bore stents. This problem was typically solved by exchanging the echoendoscope for a therapeutic endoscope after EUS-guided tattooing of the best puncture site [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, with the development of therapeutic echoendoscopes (working channel 3.7 mm; Pentax FG32UA, Pentax Precision Instruments, Inc, Orangeburg, NY; ALOKA curvilinear array echoendoscope, Olympus, Inc, Center Valley, PA), needle puncture, guidewire placement, and 10F stents placement can be carried out under fluoroscopic guidance using a single instrument (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70020 \" href=\"UTD.htm?2/62/3042\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76019 \" href=\"UTD.htm?23/50/24367\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81350 \" href=\"UTD.htm?11/18/11552\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51572 \" href=\"UTD.htm?6/26/6561\">",
"     picture 2",
"    </a>",
"    ).Furthermore, an endoscopically visible bulge is not necessary to safely perform transmural drainage and its flow Doppler capability permits the detection and avoidance of intervening blood vessels during needle access [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/8-13\">",
"     8-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As expertise increases, EUS is becoming increasingly utilized for pseudocyst drainage. Although large prospective, randomized studies comparing EUS to duodenoscope-assisted drainage have not been performed, observational data suggest that EUS may change management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 32 patients referred for endoscopic pseudocyst drainage, EUS was performed prior to drainage. Inappropriate therapy was avoided in 12 patients: a treatable pseudocyst was not identified in five, the distance between the gut and the cyst was too large in four, varices were present between the cyst and the gut in two, and normal pancreatic parenchyma was present between the cyst and the gut in one. However, it is likely that these findings could have been detected by endoscopic needle localization and preprocedural thin-cut contrast-enhanced CT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main advantage to EUS remains the ability to detect unsuspected perigastric varices and to perform transmural drainage in the absence of an endoscopically visible bulge, particularly for lesions in the tail of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/14\">",
"     14",
"    </a>",
"    ]. An additional advantage of EUS-guided drainage is that the stylet from a 19G needle can be removed, and a 0.035\" guidewire can be passed through the needle under direct ultrasound visualization and with fluoroscopy guidance to assess for adequate looping of the wire within the pseudocyst cavity. Additional maneuvers are similar to the conventional drainage described below. (See",
"    <a class=\"local\" href=\"#H42782463\">",
"     'Technique following localization of the puncture site'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A single center prospective series included 99 patients in whom either conventional endoscopic drainage in the setting of an obvious bulge without portal hypertension (N = 53) or EUS-guided drainage (N = 46) was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/15\">",
"     15",
"    </a>",
"    ]. Short-term success (94 versus 93 percent) and complications (18 versus 19 percent) were similar between the two groups. However, because of the study design, the groups had variable patient characteristics. Patients who underwent EUS-guided drainage lacked an endoscopically visible bulge or potentially had suspected portal hypertension and thus may have represented a higher risk population.",
"   </p>",
"   <p>",
"    One potential disadvantage of the EUS-guided drainage is the oblique view compared with the side-view of the duodenoscope. However, tangential puncture does not appear to be associated with higher rates of incomplete drainage or complications. A promising development is the production of a front-viewing therapeutic echoendoscope (Olympus, Inc.), but it lacks an elevator [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/16\">",
"     16",
"    </a>",
"    ]. It is not yet commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782463\">",
"    <span class=\"h2\">",
"     Technique following localization of the puncture site",
"    </span>",
"    &nbsp;&mdash;&nbsp;For conventional transmural drainage,",
"    <strong>",
"    </strong>",
"    a perpendicular axis between the needle and the endoscopically visible bulge is sought to allow for limited injection of contrast to outline the pseudocyst. Maintaining needle position within the pseudocyst during advancement of the needle-knife papillotome (HPC2, Cook Endoscopy, Inc, Winston-Salem, NC) side-by-side permits anchoring of the duodenoscope position. The needle-knife has a similar precurve that tends to follow the HBAN22, bringing the diathermic needle adjacent to the penetrating needle at a similar angle.",
"   </p>",
"   <p>",
"    To create the cystenterostomy, a brief burst of blended cutting current is applied during firm pressure of the needle-knife on the bulge. Stroking the pseudocyst bulge with the needle-knife is not recommended since a cut of as little as a few millimeters may inadvertently enter an adjacent gastric wall vessel. Some chronic pseudocysts and transgastric punctures may require more current to achieve entry.",
"   </p>",
"   <p>",
"    As soon as the needle-knife enters the cavity, electrocautery is discontinued immediately to avoid diathermic injury to adjacent structures. The HBAN22 is then withdrawn and the inner needle of the HPC2 is removed, with subsequent placement of a 450 cm long flexible guidewire through the remaining 5 Fr catheter. We prefer a hydrophilic angled wire (Tracer Metro, Cook Endoscopy, Inc, Winston-Salem, NC, or Jagwire, Boston Scientific Corp, Natick, MA) to minimize the potential for perforation of the opposite wall.",
"   </p>",
"   <p>",
"    The 5 Fr catheter is exchanged over the guidewire for an 8 mm or 10 mm hydrostatic balloon (Wireguided CRE, Boston Scientific Corp, Natick, MA; Titan, Cook Endoscopy, Inc, Winston-Salem, NC; or Quantum, Cook Endoscopy, Inc, Winston-Salem, NC) to dilate the cystenterostomy. During balloon dilation, it is important to visualize a \"waist\" between the GI lumen and pseudocyst to assure that adequate tract dilation is achieved. Finally, we place two or more 10 Fr, double-pigtailed stents, (Hobbs Medical, Inc, Stafford Springs, CT, or Solex&trade;, Cook Endoscopy, Inc, Winston-Salem, NC) using a guide catheter and pusher tube system (Oasis, Cook Endoscopy, Inc, Winston-Salem, NC). After the initial stent deployment, the Fusion system (Cook Endoscopy, Inc, Winston-Salem, NC) can be used to maintain wire position within the pseudocyst for additional stents, obviating the need to recannulate the cavity with the guidewire. In the presence of a very large pseudocyst, we vary the angle and length of the stents to permit drainage of the most dependent and distant portions.",
"   </p>",
"   <p>",
"    An alternative technique for drainage involves the Needle-Wire Oasis System (Cook Endoscopy, Inc, Winston-Salem, NC). Following diathermic needle puncture of the pseudocyst, the internal rigid part of the needle wire is removed with the guidewire curled into the cavity. The tract is expanded using the dilator catheter followed by the advancement of the stent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/17\">",
"     17",
"    </a>",
"    ]. A straight, preloaded stent is then advanced to permit a one-step drainage procedure. A possible disadvantage is that straight stents may be more likely to migrate and cause perforation compared with double-pigtail stents, and additional balloon dilation may be necessary to expand the tract for additional stent placement. This device has been used in conjunction with EUS puncture with guidewire placement as a one-step procedure. One study reported an 88 percent success rate in 35 consecutive pseudocyst patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A final puncture technique uses a 10 Fr electrosurgical device (Cystotome, Cook Endoscopy, Inc, Winston-Salem, NC), which permits direct puncture followed by diathermic cautery to leave a pseudocyst enterostomy greater than 10 Fr upon healing. The procedure is generally completed with a single transmural stent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/19\">",
"     19",
"    </a>",
"    ]. However, a newer technique of exchanging the guidewire inside the cavity has been described to enable multiple stents to be placed after puncture with the Cystotome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the retrieved fluid is turbid, contains debris, or if the patient has known pancreatic necrosis, we often repeat the dilation to extend the cystenterostomy, allowing placement of up to four stents. In addition, a 7 or 8.5 Fr nasobiliary drain is placed to permit pseudocyst lavage with sterile normal saline, which is performed for several days. In larger pseudocysts, or if underlying necrosis is detected by EUS or computed tomography (CT), we have used a technique to lavage pseudocysts at home for up to several weeks, with the aid of a home health agency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous endoscopic gastrostomy can also be performed with placement of an irrigating catheter into the pseudocyst for long-term irrigation if nasocystic tubes are not tolerated. As a general rule, success can be achieved as an alternative to surgery, but requires repeated endoscopies for lavage, additional tract dilation, stents, and endoscopic necrosectomy using snares, nets, baskets, and forceps. It is important to discuss with the patient the potential for additional procedures to achieve adequate necrosectomy in advance of the first endoscopic procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=see_link\">",
"     \"Endoscopic management of pseudocysts of the pancreas: Efficacy and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782471\">",
"    <span class=\"h2\">",
"     Postdrainage care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to admit patients following pseudocyst drainage depends partly on endoscopist preference and if there is underlying necrosis or debris that may require two to three days of nasocystic lavage. Most patients receive a short course of a quinolone or broader-spectrum antibiotic that can be tailored to the culture results obtained at the time of endoscopic drainage.",
"   </p>",
"   <p>",
"    We follow our patients with a CT scan or follow-up EUS in four to six weeks and, if there is complete collapse, the stents are removed. However, one study suggested that pseudocyst recurrence may be reduced if the stents are left in for a longer duration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/22\">",
"     22",
"    </a>",
"    ]. Long-term post-transmural drainage stents appear to prevent recurrence when major duct disruption prevented drainage back to the duodenum from a disconnected, functioning up-stream portion of the pancreas. The thought is that the cystenterostomy fistulous connection matures and persists after stent removal.",
"   </p>",
"   <p>",
"    Detection of a disconnected pancreatic tail segment can be confirmed with dynamic contrast helical CT coupled with endoscopic retrograde cholangiopancreatography (ERCP).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     Secretin",
"    </a>",
"    stimulated magnetic resonance cholangiopancreatography may be an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending on the degree of biliary obstruction from pseudocyst compression, sphincterotomy and biliary stent placement may be performed, followed by a subsequent repeat cholangiogram and withdrawal of the biliary stent at a second ERCP if adequate pseudocyst resolution has been achieved.",
"   </p>",
"   <p>",
"    In patients whose pseudocysts have not resolved in four to six weeks, we generally perform repeat cystenterostomy tract dilation and stent replacement in an attempt to achieve complete pseudocyst collapse and drainage. Often, the reason for a lack of resolution may be related to underlying necrosis in which endoscopic necrosectomy may be performed at the follow-up examination and may require multiple endoscopic sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/24\">",
"     24",
"    </a>",
"    ]. If there are multiple compartments or undrained segments away from the original cystenterostomy, then additional transmural puncture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transpapillary stent placement (see below) may be required for resolution. Percutaneous drainage of those collections away from the intestinal lumen may be necessary. Referral to surgery is considered for non-resolution of pseudocysts or in the presence of acutely infected organized necrosis that lacks a mature wall for drainage.",
"   </p>",
"   <p>",
"    Throughout the follow-up period, patients are cautioned that any change in symptoms, particularly fever, should be promptly reported. In many such cases, reevaluation discloses stent malfunction or pseudocyst loculation with subsequent infection, both of which can be managed with further endoscopic intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782485\">",
"    <span class=\"h1\">",
"     TRANSPAPILLARY STENT PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;To begin transpapillary pancreatic stent placement, we perform endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy to avoid the theoretical risk of transient biliary obstruction due to pancreatic sphincterotomy. Deep entry into the pancreatic duct is then achieved and a hydrophilic guidewire is maneuvered either into the pseudocyst or across the leak toward the pancreatic tail. We perform pancreatic sphincterotomy using a monofilament papillotome over a guidewire, extending the cut to a length of 5 to 10 mm to completely incise the sphincter. In the presence of a dense pancreatic duct stricture or a pancreatic duct stone, we perform dilation with either a hard plastic dilator or hydrostatic balloon followed by stent placement (7F or 8.5F).",
"   </p>",
"   <p>",
"    Prophylactic and postprocedural antibiotics are provided for seven days. The stent is removed after pseudocyst resolution is achieved; however, it may be necessary to address pancreatic ductal obstruction caused by strictures or stones to reduce pseudocyst recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H42782501\">",
"     'Combined transmural drainage and transpapillary stent placement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782493\">",
"    <span class=\"h2\">",
"     Abscess drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transpapillary approach to managing pancreatic abscesses has been described in a report involving 11 patients who were considered to be high-risk for surgical drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/25\">",
"     25",
"    </a>",
"    ]. Pancreatic sphincterotomy was performed and a guide catheter was advanced into the abscess cavity; sterile saline irrigation was continued until the clearance of pus and contrast material. A 10 Fr pancreatic stent was then placed into the abscess and across the papilla. Routine follow-up was scheduled for six weeks. The mean number of ERCPs per patient was 2.2 with a mean length of stay of 110 days, an overall success rate of 74 percent, and a mortality rate of 9 percent. The results were comparable to a group of 13 patients (including two patients who failed endoscopic drainage) who had undergone surgery (mean hospital stay 140 days, 76 percent success rate, and 13 percent mortality). The prolonged hospitalization and high mortality rates reflect the severity of illness in this population.",
"   </p>",
"   <p>",
"    We prefer a transmural approach to a transpapillary approach for abscess drainage since it permits further cystenterostomy tract dilation, nasocystic irrigation, and placement of multiple stents to prevent difficulties with stent malfunction and retained debris.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782501\">",
"    <span class=\"h1\">",
"     COMBINED TRANSMURAL DRAINAGE AND TRANSPAPILLARY STENT PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some endoscopists have advocated combining transmural puncture and stent placement to ensure pseudocyst drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. However, both procedures carry significant additive risks, and comparative data have not been presented to document increased success. A large series from Brussels included patients who underwent either transmural (both conventional and EUS-guided), transpapillary, or both methods of drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/30\">",
"     30",
"    </a>",
"    ]. Those with combined approaches had a higher rate of pseudocyst recurrence in comparison with patients who underwent transpapillary or transmural drainage alone (27 versus 4 to 20 percent). One potential explanation is the transpapillary stent may hinder the maturation of the cystenterostomy fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another large retrospective series compared 40 patients who received combined transmural and transpapillary drainage for pancreatic fluid collections with 70 patients who underwent transmural drainage alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27655/abstract/31\">",
"     31",
"    </a>",
"    ]. The success rate for combined treatment was higher (98 versus 80 percent). However, the patients receiving transmural drainage alone were those with a completely disrupted pancreatic duct, gastric outlet obstruction, altered anatomy, or absence of a definitive leak.",
"   </p>",
"   <p>",
"    In view of the high likelihood of success with transmural drainage and transpapillary stent placement (in properly selected patients) alone, combined procedures should probably be limited to special situations in order to minimize complications. We currently perform combined procedures only for very large pseudocysts in the setting of pancreatic duct strictures or obstructing stones, particularly if the cyst contains thick fluid or debris.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42782509\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic drainage is the procedure of choice in the management of most patients with pseudocysts of the pancreas.",
"     </li>",
"     <li>",
"      There are two primary techniques for the endoscopic management of pancreatic pseudocysts: transmural puncture and transpapillary stent placement.",
"     </li>",
"     <li>",
"      We attempt transmural puncture in patients who have large, symptomatic pseudocysts compressing the stomach or duodenum when there is close apposition seen on computed tomography scan. (See",
"      <a class=\"local\" href=\"#H42782425\">",
"       'Endoscopic transmural drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with relatively small pseudocysts in communication with the main pancreatic duct are considered good candidates for transpapillary stent placement as initial therapy. (See",
"      <a class=\"local\" href=\"#H42782485\">",
"       'Transpapillary stent placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adding endoscopic ultrasound to the transmural drainage procedure may detect unsuspected perigastric varices and allows for transmural drainage in the absence of an endoscopically visible bulge, particularly for lesions in the tail of the pancreas. (See",
"      <a class=\"local\" href=\"#H42782455\">",
"       'Endoscopic ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some endoscopists have advocated combining transmural puncture and stent placement to ensure pseudocyst drainage. However, both procedures carry significant additive risks, and comparative data have not been presented to document increased success. (See",
"      <a class=\"local\" href=\"#H42782501\">",
"       'Combined transmural drainage and transpapillary stent placement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/1\">",
"      Jacobson BC, Baron TH, Adler DG, et al. ASGE guideline: The role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc 2005; 61:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/2\">",
"      Giovannini M, Pesenti C, Rolland AL, et al. Endoscopic ultrasound-guided drainage of pancreatic pseudocysts or pancreatic abscesses using a therapeutic echo endoscope. Endoscopy 2001; 33:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/3\">",
"      Mani V, Cartwright K, Dooley J, et al. Antibiotic prophylaxis in gastrointestinal endoscopy: a report by a Working Party for the British Society of Gastroenterology Endoscopy Committee. Endoscopy 1997; 29:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/4\">",
"      Howell DA, Holbrook RF, Bosco JJ, et al. Endoscopic needle localization of pancreatic pseudocysts before transmural drainage. Gastrointest Endosc 1993; 39:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/5\">",
"      Kozarek RA. Endoscopic treatment of pancreatic pseudocysts. Gastrointest Endosc Clin N Am 1997; 7:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/6\">",
"      Cremer M, Deviere J, Engelholm L. Endoscopic management of cysts and pseudocysts in chronic pancreatitis: long-term follow-up after 7 years of experience. Gastrointest Endosc 1989; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/7\">",
"      M&ouml;nkem&uuml;ller KE, Baron TH, Morgan DE. Transmural drainage of pancreatic fluid collections without electrocautery using the Seldinger technique. Gastrointest Endosc 1998; 48:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/8\">",
"      Fockens P, Johnson TG, van Dullemen HM, et al. Endosonographic imaging of pancreatic pseudocysts before endoscopic transmural drainage. Gastrointest Endosc 1997; 46:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/9\">",
"      Grimm H, Binmoeller KF, Soehendra N. Endosonography-guided drainage of a pancreatic pseudocyst. Gastrointest Endosc 1992; 38:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/10\">",
"      Savides TJ, Gress F, Sherman S, et al. Ultrasound catheter probe-assisted endoscopic cystgastrostomy. Gastrointest Endosc 1995; 41:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/11\">",
"      Wiersema MJ. Endosonography-guided cystoduodenostomy with a therapeutic ultrasound endoscope. Gastrointest Endosc 1996; 44:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/12\">",
"      Seifert H, Dietrich C, Schmitt T, et al. Endoscopic ultrasound-guided one-step transmural drainage of cystic abdominal lesions with a large-channel echo endoscope. Endoscopy 2000; 32:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/13\">",
"      Antillon MR, Shah RJ, Stiegmann G, Chen YK. Single-step EUS-guided transmural drainage of simple and complicated pancreatic pseudocysts. Gastrointest Endosc 2006; 63:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/14\">",
"      Varadarajulu S, Wilcox CM, Tamhane A, et al. Role of EUS in drainage of peripancreatic fluid collections not amenable for endoscopic transmural drainage. Gastrointest Endosc 2007; 66:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/15\">",
"      Kahaleh M, Shami VM, Conaway MR, et al. Endoscopic ultrasound drainage of pancreatic pseudocyst: a prospective comparison with conventional endoscopic drainage. Endoscopy 2006; 38:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/16\">",
"      Sanders MK, Aoun, Elie. Experience with a Prototype Forward-Viewing Curvilinear Array Therapeutic Echoendoscope for Interventional EUS: A Case Series. Gastrointestinal Endoscopy 2010; 71:AB102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/17\">",
"      Giovannini M. EUS-guided pancreatic pseudocyst drainage. Tech Gastrointest Endosc 2007; 9:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/18\">",
"      Kr&uuml;ger M, Schneider AS, Manns MP, Meier PN. Endoscopic management of pancreatic pseudocysts or abscesses after an EUS-guided 1-step procedure for initial access. Gastrointest Endosc 2006; 63:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/19\">",
"      Ahlawat SK, Charabaty-Pishvaian A, Jackson PG, Haddad NG. Single-step EUS-guided pancreatic pseudocyst drainage using a large channel linear array echoendoscope and cystotome: results in 11 patients. JOP 2006; 7:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/20\">",
"      Jansen JM, Hanrath A, Rauws EA, et al. Intracystic wire exchange facilitating insertion of multiple stents during endoscopic drainage of pancreatic pseudocysts. Gastrointest Endosc 2007; 66:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/21\">",
"      Baron TH, Thaggard WG, Morgan DE, Stanley RJ. Endoscopic therapy for organized pancreatic necrosis. Gastroenterology 1996; 111:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/22\">",
"      Arvanitakis M, Delhaye M, Bali MA, et al. Pancreatic-fluid collections: a randomized controlled trial regarding stent removal after endoscopic transmural drainage. Gastrointest Endosc 2007; 65:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/23\">",
"      Gillams AR, Kurzawinski T, Lees WR. Diagnosis of duct disruption and assessment of pancreatic leak with dynamic secretin-stimulated MR cholangiopancreatography. AJR Am J Roentgenol 2006; 186:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/24\">",
"      Seifert H, Biermer M, Schmitt W, et al. Transluminal endoscopic necrosectomy after acute pancreatitis: a multicentre study with long-term follow-up (the GEPARD Study). Gut 2009; 58:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/25\">",
"      Venu RP, Brown RD, Marrero JA, et al. Endoscopic transpapillary drainage of pancreatic abscess: technique and results. Gastrointest Endosc 2000; 51:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/26\">",
"      Barthet M, Sahel J, Bodiou-Bertei C, Bernard JP. Endoscopic transpapillary drainage of pancreatic pseudocysts. Gastrointest Endosc 1995; 42:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/27\">",
"      Catalano MF, Geenen JE, Schmalz MJ, et al. Treatment of pancreatic pseudocysts with ductal communication by transpapillary pancreatic duct endoprosthesis. Gastrointest Endosc 1995; 42:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/28\">",
"      Smits ME, Rauws EA, Tytgat GN, Huibregtse K. The efficacy of endoscopic treatment of pancreatic pseudocysts. Gastrointest Endosc 1995; 42:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/29\">",
"      Binmoeller KF, Seifert H, Walter A, Soehendra N. Transpapillary and transmural drainage of pancreatic pseudocysts. Gastrointest Endosc 1995; 42:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/30\">",
"      Hookey LC, Debroux S, Delhaye M, et al. Endoscopic drainage of pancreatic-fluid collections in 116 patients: a comparison of etiologies, drainage techniques, and outcomes. Gastrointest Endosc 2006; 63:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27655/abstract/31\">",
"      Trevino JM, Tevino JM, Tamhane A, Varadarajulu S. Successful stenting in ductal disruption favorably impacts treatment outcomes in patients undergoing transmural drainage of peripancreatic fluid collections. J Gastroenterol Hepatol 2010; 25:526.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5650 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-F3B3B15694-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27655=[""].join("\n");
var outline_f27_0_27655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42782509\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42782401\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42782409\">",
"      CHOICE OF PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42782417\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42782425\">",
"      ENDOSCOPIC TRANSMURAL DRAINAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42782433\">",
"      Endoscopic needle localization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42782441\">",
"      - Diathermic puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42782448\">",
"      - Seldinger technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42782455\">",
"      Endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42782463\">",
"      Technique following localization of the puncture site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42782471\">",
"      Postdrainage care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42782485\">",
"      TRANSPAPILLARY STENT PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42782493\">",
"      Abscess drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42782501\">",
"      COMBINED TRANSMURAL DRAINAGE AND TRANSPAPILLARY STENT PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42782509\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5650|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/62/3042\" title=\"diagnostic image 1\">",
"      EUS panc pseudocyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/50/24367\" title=\"diagnostic image 2\">",
"      Fluoroscopy balloon dilat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5650|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/18/11552\" title=\"picture 1\">",
"      Purulent drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/26/6561\" title=\"picture 2\">",
"      Transgastr pigtail stents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=related_link\">",
"      Diagnosis and management of pseudocysts of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=related_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Efficacy and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=related_link\">",
"      Pancreatic cystic neoplasms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_0_27656="Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features";
var content_f27_0_27656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27656/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27656/contributors\">",
"     James R Gossage, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27656/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27656/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/0/27656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary arteriovenous malformations (PAVM) are abnormal communications between pulmonary veins and arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/1\">",
"     1",
"    </a>",
"    ]. Alternative names include pulmonary arteriovenous fistulae, pulmonary arteriovenous aneurysms, cavernous angiomas of the lung, and pulmonary telangiectases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/2\">",
"     2",
"    </a>",
"    ]. PAVM are uncommon, but they are an important consideration in the differential diagnosis of common pulmonary problems, including hypoxemia, pulmonary nodules, and hemoptysis.",
"   </p>",
"   <p>",
"    The epidemiology, etiology, pathology, and clinical features of PAVM are reviewed here. The diagnosis and treatment of PAVM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32263?source=see_link\">",
"     \"Pulmonary arteriovenous malformations: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAVM are uncommon. This was illustrated by a study of 15,000 consecutive autopsies, in which only three cases of PAVM were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/2\">",
"     2",
"    </a>",
"    ]. Small PAVM can be missed in routine autopsies and may have contributed to the low prevalence in this study; however, there are additional data to support the findings. Three case series from the Mayo Clinic reported 194 cases of PAVM over 45 years, indicating an annual incidence of only 4.3 cases per year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. PAVM are twice as common among women, compared with men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PAVM vary in their number, distribution, and size. This was demonstrated by a study that evaluated 350 patients with PAVM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/7\">",
"     7",
"    </a>",
"    ]. The study found that 36 percent of patients had multiple lesions and 25 percent had bilateral disease. More than half of the lesions were in the lower lung fields and almost 80 percent involved the pleura. Other studies indicate that PAVM are typically 1 to 5 cm in size (but occasionally exceed 10 cm) and that 7 to 11 percent of patients have diffuse microvascular PAVM that may occur in combination with radiographically visible PAVM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. PAVM tend to increase in size over time and rarely regress spontaneously.",
"   </p>",
"   <p>",
"    It was previously estimated that 70 percent of cases of PAVM are associated with hereditary hemorrhagic telangiectasia (HHT, also called Osler-Weber-Rendu syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/10\">",
"     10",
"    </a>",
"    ]. However, more recent reports from HHT treatment centers suggest that the true value may be higher, with at least 80 to 90 percent of patients with PAVM having underlying HHT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/11\">",
"     11",
"    </a>",
"    ]. In our experience with over 150 patients with PAVM, HHT was either confirmed or strongly suspected in at least 98 percent of the patients with macroscopic PAVM. Conversely, only about 30 to 40 percent of patients with HHT have visible PAVM on chest CT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ], although this appears to be substantially higher among patients with the HHT1 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/6\">",
"     6",
"    </a>",
"    ]. HHT-associated PAVM are uncommon during infancy or childhood, and then gradually increase in incidence through the fifth and sixth decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise cause of PAVM is unknown. However, numerous causes of PAVM have been proposed, including the following: aberrant TGF-beta signaling during vascular development, possibly involving endoglin or activin receptor-like kinase 1; a defect in terminal arterial loops that allows dilation of thin-walled capillary sacs; incomplete resorption of the vascular septae that separate the arterial and venous plexuses during fetal development; failure of capillary development during fetal development, followed by the progressive dilation of favored limbs of smaller plexuses, formation of multiloculated sacs, and rupture of intervening vascular walls; and, development of many small PAVM consisting of a single artery-to-vein connection without an intervening plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While most PAVM are congenital, PAVM can occur in a variety of acquired medical conditions. The most common association is hepatic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/17\">",
"     17",
"    </a>",
"    ], while less common associations include penetrating chest trauma, mitral stenosis, schistosomiasis, actinomycosis, Fanconi's syndrome, and metastatic thyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. PAVM are also a well-established complication following surgery for congenital heart disease in children, including the classic Glenn shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/19\">",
"     19",
"    </a>",
"    ] and bidirectional cavopulmonary anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/20\">",
"     20",
"    </a>",
"    ]. The mechanism by which these various medical conditions become associated with PAVM is unknown.",
"   </p>",
"   <p>",
"    The genetics and pathogenesis of hereditary hemorrhagic telangiectasia (HHT) may also provide insights into the etiology of PAVM. They are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link&amp;anchor=H5#H5\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAVM appear macroscopically as a large single sac, a plexiform mass of dilated vascular channels, or a dilated and tortuous direct anastomosis between an artery and vein [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/7\">",
"     7",
"    </a>",
"    ]. Histologically, PAVM are usually thin-walled, consisting of a single layer of endothelium and variable amounts of connective tissue stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/2\">",
"     2",
"    </a>",
"    ]. Calcification and mural thrombosis are occasionally seen.",
"   </p>",
"   <p>",
"    PAVM are classified as either simple or complex. Simple PAVM are perfused by arteries arising from a single subsegmental artery, whereas complex PAVM are perfused by more than one subsegmental artery. Eighty to 95 percent of PAVM are simple [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Small microvascular PAVM (ie, telangiectases) are most commonly of the complex type [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PAVM are supplied by pulmonary arteries in about 95 percent of cases and are usually drained by pulmonary veins; however, they may occasionally be fed by systemic arteries",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drain into the left atrium or inferior vena cava. When PAVM are fed by systemic arteries, hereditary hemorrhagic telangiectasia (HHT) is usually not the cause of the PAVM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with PAVM, approximately 75 percent have symptoms attributable to either the PAVM or the underlying hereditary hemorrhagic telangiectasia (HHT). Symptoms related to PAVM typically begin during the fourth through sixth decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/15\">",
"     15",
"    </a>",
"    ], whereas symptoms of HHT frequently develop before the age of 20 (eg, epistaxis due to nasal telangiectases or appearance of telangiectases on the skin (",
"    <a class=\"graphic graphic_table graphicRef74593 \" href=\"UTD.htm?12/12/12493\">",
"     table 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms attributable to PAVM include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dyspnea is the most common complaint directly attributable to the PAVM; it is seen in about half of patients with PAVM [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/22,24\">",
"       22,24",
"      </a>",
"      ]. Dyspnea is especially common among patients with clubbing and among patients whose PAVM are large, multiple, bilateral, or diffuse [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/16\">",
"       16",
"      </a>",
"      ]. It may occasionally be caused by high output heart failure due to hepatic AVM in patients with HHT [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemoptysis may be massive and has a predilection to occur during the latter part of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/16\">",
"       16",
"      </a>",
"      ]. It has been hypothesized that PAVM may be exacerbated during pregnancy by the increased blood volume, cardiac output, and vascular distensibility, all of which promote increased blood flow through PAVM. This is especially likely during the third trimester. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=see_link\">",
"       \"Etiology and evaluation of hemoptysis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"       \"Massive hemoptysis: Initial management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Platypnea (ie, an increase in dyspnea induced by the upright position and relieved by recumbency) may be observed and is often associated with orthodeoxia (ie, a decrease in the oxyhemoglobin saturation when rising from the supine to the upright position). Platypnea is believed to be the result of increased blood flow through PAVM in the dependent portions of the lungs upon assuming the upright position. Platypnea is not unique to PAVM, it may also occur with the hepatopulmonary syndrome, atrial septal defects (including patent foramen ovale), and other conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of symptoms tends to be greater among those who have large PAVM, more PAVM, a larger shunt fraction, or HHT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/3,4,26,27\">",
"     3,4,26,27",
"    </a>",
"    ]. Diffuse microvascular PAVM are always symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/5\">",
"     5",
"    </a>",
"    ]. Other symptoms that are common among patients with PAVM include chest pain, cough, migraine headaches, tinnitus, dizziness, dysarthria, syncope, vertigo, and diplopia.",
"   </p>",
"   <p>",
"    The most common physical findings in patients with PAVM are telangiectases on the skin and mucous membranes, due to underlying HHT. They are usually flat or slightly papular, ruby colored, 1 to 3 mm in diameter, and sharply demarcated from the surrounding skin. In addition, they tend to blanch easily with pressure and are most commonly located on the face, tongue, lips, and distal upper extremities (",
"    <a class=\"graphic graphic_picture graphicRef77416 \" href=\"UTD.htm?10/34/10786\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/14\">",
"     14",
"    </a>",
"    ]. These characteristics differentiate telangiectases on the skin from the spider nevi that are common in advanced liver disease (ie, spider nevi are always flat, blanch readily, refill centrally first, and are mainly found on the face and anterior chest). Capillary microscopy of the finger nail bed is a simple and noninvasive technique that may occasionally reveal abnormal capillary loops in patients without characteristic telangiectases.",
"   </p>",
"   <p>",
"    Digital clubbing and cyanosis were often seen in more than half of patients in older series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/2,26\">",
"     2,26",
"    </a>",
"    ], but they have been observed less often in subsequent series. Almost all patients with diffuse PAVM have clubbing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, murmurs or bruits auscultated over the PAVM were commonly reported in older series, but more recent studies indicate that they are auscultated in less than 10 percent of cases of PAVM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/4\">",
"     4",
"    </a>",
"    ]. The murmurs are loudest during inspiration and when the PAVM is in a dependent position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link&amp;anchor=H56#H56\">",
"     \"Auscultation of cardiac murmurs\", section on 'Arteriovenous fistulas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of various clinical findings is shown in the table and derives primarily from case series from single institutions (",
"    <a class=\"graphic graphic_table graphicRef79966 \" href=\"UTD.htm?36/26/37291\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/3-5,9,22,29,30\">",
"     3-5,9,22,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22399108\">",
"    <span class=\"h2\">",
"     Imaging findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs are abnormal in most patients who have symptoms attributable to PAVM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/3-5,30,31\">",
"     3-5,30,31",
"    </a>",
"    ]. Typical PAVM have the following characteristics on a conventional chest radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57484 \" href=\"UTD.htm?26/45/27344\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/2,4,7,12,27,31\">",
"     2,4,7,12,27,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Round or oval mass of uniform density.",
"     </li>",
"     <li>",
"      Sharply defined borders.",
"     </li>",
"     <li>",
"      Occasional lobulation.",
"     </li>",
"     <li>",
"      Usually 1 to 5 cm in diameter, but occasionally exceeding 9 to 10 cm in diameter.",
"     </li>",
"     <li>",
"      Usually 2 to 8 lesions among the patients who have multiple PAVM.",
"     </li>",
"     <li>",
"      Linear shadows representative of feeding vessels. They are usually 4 to 7 mm in diameter, with the artery radiating from the hilus and the vein deviating toward the left atrium [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discrete PAVM are occasionally obscured by the diaphragms or concomitant parenchymal lung disease.",
"   </p>",
"   <p>",
"    Computed tomography (CT) is more sensitive than conventional chest radiography for detecting PAVM. CT identifies nearly all PAVM, even those that are poorly appreciated on conventional chest radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56072 \" href=\"UTD.htm?3/22/3426\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Pulmonary angiography is occasionally required for definitive diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54651 \" href=\"UTD.htm?21/7/21616\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, while a completely normal chest radiograph makes the diagnosis of symptomatic PAVM less likely, it should not preclude further evaluation with CT or angiography, particularly in a patient with other features consistent with PAVM or HHT. As an example, CT of the chest may demonstrate PAVM in a patient with multiple small telangiectases, even if the conventional chest radiograph was normal or had only a vague increase in pulmonary vascular markings at the bases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physiological tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PAVM have hypoxemia. In a series of 101 patients with PAVM for whom there was information on oxyhemoglobin saturation, only 6 percent had an arterial oxyhemoglobin saturation (SaO2) of 96 percent or higher [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/7\">",
"     7",
"    </a>",
"    ]. Thirty two percent of cases had an SaO2 &lt;76 percent.",
"   </p>",
"   <p>",
"    Patients with diffuse PAVM are uniformly hypoxemic, with a mean arterial oxygen tension (PaO2) of 47 mmHg according to a series of 16 patients with PAVM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/28\">",
"     28",
"    </a>",
"    ]. Other case series have found that 81 to 100 percent of patients with PAVM have either a PaO2 &lt;80 mmHg or an SaO2 &lt;97 to 98 percent on room air [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/4,5,27\">",
"     4,5,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orthodeoxia is the laboratory correlate of platypnea. It is defined as a decrement in oxyhemoglobin saturation when rising from the supine to the upright position. In a study of 53 patients with PAVM referred for embolotherapy, the average decrease in oxyhemoglobin saturation was 6 percent upon changing from the supine to the standing position [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/34\">",
"     34",
"    </a>",
"    ]. Several other studies have found orthodeoxia in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/9,35\">",
"     9,35",
"    </a>",
"    ]. Although orthodeoxia appears to be quite common in patients with PAVM, the true incidence is difficult to estimate since all studies have suffered from selection bias.",
"   </p>",
"   <p>",
"    The presence and magnitude of right-to-left shunting can be confirmed by either assessing the response to inhaling 100 percent oxygen or documenting the appearance of technetium 99-labeled albumin macroaggregates in the brain. The latter indicates that the normal pulmonary capillaries have been circumvented [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard spirometric indices are usually within normal limits in patients with PAVM. However, the diffusing capacity may be mildly elevated and resting minute ventilation is usually increased [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/35\">",
"     35",
"    </a>",
"    ]. Chronic respiratory alkalosis may also be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high quality studies of pulmonary hemodynamics in patients with PAVM. However, it appears that patients with diffuse PAVM typically have normal pulmonary artery pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/28\">",
"     28",
"    </a>",
"    ]. This was supported by a review that included 88 patients with PAVM and reported that the mean pulmonary artery pressure was normal or low in 91 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 10 percent of patients with PAVM and HHT have pulmonary hypertension, according to a study of 143 patients undergoing PAVM embolization that found that 9 percent of patients had a mean pulmonary artery pressure &gt;20 mm Hg and 6 percent had a pressure &gt;25 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/37\">",
"     37",
"    </a>",
"    ]. Pulmonary hypertension in patients with PAVM is generally due to one or more of the following causes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent cause is high output heart failure due to right to left shunting from hepatic artery to hepatic vein AVMs. Such patients typically have an elevated pulmonary artery occlusion pressure, a markedly increased cardiac index, and a normal pulmonary vascular resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/25\">",
"       25",
"      </a>",
"      ]. The elevated pulmonary venous pressure and flow may predispose to enlargement of the underlying PAVM [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link\">",
"       \"High-output heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients may have portopulmonary hypertension due to portal hypertension caused by a hepatic AVM. The pulmonary artery wedge pressure is usually normal and the pulmonary vascular resistance is increased. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=see_link\">",
"       \"Portopulmonary hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients can have coexisting HHT and pulmonary arterial hypertension, which may be related to defects in ALK-1. ALK-1 is the product of the HHT 2 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. Ten patients with pulmonary hypertension have been identified from four families with HHT [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/40\">",
"       40",
"      </a>",
"      ]. Histology was available from four of the patients and was consistent with idiopathic pulmonary arterial hypertension. Genetic linkage analysis was consistent with alterations in ALK-1, rather than changes in endoglin or BMPR2 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/41\">",
"       41",
"      </a>",
"      ]. The latter gene is known to be involved in idiopathic pulmonary arterial hypertension. Generally speaking, pulmonary AVM are uncommon among patients with pulmonary hypertension due to ALK-1 mutations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several patients have developed new or increased pulmonary hypertension following embolization or resection of a large PAVM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exercise physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PAVM have reduced exercise tolerance; however, their exercise tolerance tends to be better maintained than patients who have an equivalent degree of hypoxemia from another cause [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. As an example, a study of 15 patients with PAVM who were referred for balloon embolotherapy found that 11 of the 15 patients (73 percent) achieved &gt;70 percent of their predicted maximum workload despite their SaO2 decreasing from 86 percent at rest to 73 percent with peak exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients with similar degrees of hypoxemia due to other cardiac and pulmonary diseases have considerably less tolerance for exercise due to an increase in baseline pulmonary vascular resistance that prevents an appropriate increase in cardiac output during exercise. Presumably, patients with PAVM are able to increase pulmonary blood flow appropriately during exercise due to a subnormal pulmonary vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAVM can be associated with a variety of complications, some of which are life-threatening (",
"    <a class=\"graphic graphic_table graphicRef77215 \" href=\"UTD.htm?13/5/13403\">",
"     table 3",
"    </a>",
"    ). Examples include stroke, brain abscess, hemothorax, and hemoptysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stroke and brain abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently reported complications of PAVM relate to embolic material evading the filtering function of the pulmonary capillaries and reaching the central nervous system.",
"   </p>",
"   <p>",
"    A series of 76 consecutive patients undergoing embolotherapy reported that symptomatic strokes had occurred in 18 percent, transient ischemic attacks in 37 percent, brain abscesses in 9 percent, migraine headaches in 43 percent, and seizures in 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/9\">",
"     9",
"    </a>",
"    ]. The CT scans from 59 consecutive patients in this series showed unequivocal evidence of stroke in 36 percent and cerebral arteriovenous malformations in 5 percent. The incidence of stroke has averaged around 11 percent in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. Many of the studies did not perform CT scanning systematically and, therefore, that figure is probably an underestimate since small strokes may have been undetected.",
"   </p>",
"   <p>",
"    Neurologic complications are especially common in patients who have diffuse PAVM, with 70 percent of patients having stroke or brain abscess at the time of diagnosis in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/28,45\">",
"     28,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paradoxic embolization across a PAVM is the most likely mechanism for both strokes and brain abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/45\">",
"     45",
"    </a>",
"    ]. This was supported by a review of the neurologic complications of HHT, in which 25 of 28 brain abscesses (89 percent) were associated with concomitant PAVM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/46\">",
"     46",
"    </a>",
"    ]. Strokes and brain abscesses occur almost exclusively in patients with feeding arteries &gt;3 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/47\">",
"     47",
"    </a>",
"    ]. A serious central nervous system event is often the initial manifestation of an otherwise silent PAVM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hemothorax and hemoptysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemothorax and hemoptysis occur less commonly, but are potentially life-threatening. Hemothorax results from rupture of a subpleural PAVM, while hemoptysis may be due to rupture of either a parenchymal PAVM or an endobronchial telangiectasia. Pulmonary hemorrhage is often the initial symptom of PAVM. In a series of 143 patients with PAVM who were referred for embolotherapy, 11 patients (8 percent) had a history of hemoptysis or hemothorax requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=see_link\">",
"     \"Etiology and evaluation of hemoptysis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary hemorrhage commonly occurs during the latter half of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/16\">",
"     16",
"    </a>",
"    ]. Pregnancy may exacerbate PAVM through increased blood volume, increased cardiac output, and increased vascular distensibility, all of which promote increased blood flow through PAVM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia and anemia are each seen in approximately 18 percent of patients with PAVM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/3-5,30\">",
"     3-5,30",
"    </a>",
"    ]. Although not reported much in the literature, we have seen several patients with abscesses in the soft tissue, muscle, or other organs (eg, spleen), all presumably due to paradoxic embolization. PAVM may rarely be complicated by pulmonary hypertension and patients with underlying HHT can suffer from epistaxis, gastrointestinal hemorrhage, and skin bleeding (",
"    <a class=\"graphic graphic_table graphicRef74593 \" href=\"UTD.htm?12/12/12493\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27656/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1843005\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary arteriovenous malformations (PAVM) are abnormal communications between pulmonary veins and arteries. They are uncommon, but they are an important consideration in the differential diagnosis of common pulmonary problems, including hypoxemia, pulmonary nodules, and hemoptysis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PAVM are uncommon and their precise cause is unknown. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PAVM macroscopically appear as a large single sac, a plexiform mass of dilated vascular channels, or a dilated and tortuous direct anastomosis between an artery and vein. Histologically, PAVM are usually thin-walled, consisting of a single layer of endothelium and variable amounts of connective tissue stroma. Calcification and mural thrombosis are occasionally seen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with PAVM have underlying HHT, which may or may not have been diagnosed yet.",
"     </li>",
"     <li>",
"      Most patients with PAVM have symptoms attributable to either the PAVM or underlying hereditary hemorrhagic telangiectasia (HHT). Symptoms and signs attributable to the PAVM include dyspnea, hemoptysis, platypnea, and orthodeoxia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiographs are abnormal in most patients who have symptoms attributable to PAVM. However, computed tomography (CT) is more sensitive than conventional chest radiography for detecting PAVM and pulmonary angiography is occasionally required for definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H22399108\">",
"       'Imaging findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with PAVM have hypoxemia and normal pulmonary artery pressures. They also have reduced exercise tolerance, but their exercise tolerance tends to be better maintained than patients who have an equivalent degree of hypoxemia from another cause. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Physiological tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Hemodynamics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Exercise physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PAVM can be associated with a variety of complications (",
"      <a class=\"graphic graphic_table graphicRef77215 \" href=\"UTD.htm?13/5/13403\">",
"       table 3",
"      </a>",
"      ). The most frequently reported complications of PAVM relate to embolic material evading the filtering function of the pulmonary capillaries and reaching the central nervous system. Hemothorax and hemoptysis occur less commonly but are potentially life-threatening. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/1\">",
"      Churton, T. Multiple aneurysms of the pulmonary artery. Br Med J 1897; 1:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/2\">",
"      SLOAN RD, COOLEY RN. Congenital pulmonary arteriovenous aneurysm. Am J Roentgenol Radium Ther Nucl Med 1953; 70:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/3\">",
"      Swanson KL, Prakash UB, Stanson AW. Pulmonary arteriovenous fistulas: Mayo Clinic experience, 1982-1997. Mayo Clin Proc 1999; 74:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/4\">",
"      Dines DE, Arms RA, Bernatz PE, Gomes MR. Pulmonary arteriovenous fistulas. Mayo Clin Proc 1974; 49:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/5\">",
"      Dines DE, Seward JB, Bernatz PE. Pulmonary arteriovenous fistulas. Mayo Clin Proc 1983; 58:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/6\">",
"      van Gent MW, Post MC, Snijder RJ, et al. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010; 138:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/7\">",
"      BOSHER LH Jr, BLAKE DA, BYRD BR. An analysis of the pathologic anatomy of pulmonary arteriovenous aneurysms with particular reference to the applicability of local excision. Surgery 1959; 45:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/8\">",
"      Kretschmar O, Ewert P, Yigitbasi M, et al. Huge pulmonary arteriovenous fistula: diagnosis and treatment and an unusual complication of embolization. Respir Care 2002; 47:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/9\">",
"      White RI Jr, Lynch-Nyhan A, Terry P, et al. Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy. Radiology 1988; 169:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/10\">",
"      Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/11\">",
"      Pollak JS, Saluja S, Thabet A, et al. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol 2006; 17:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/12\">",
"      Vase P, Holm M, Arendrup H. Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia. Acta Med Scand 1985; 218:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/13\">",
"      Haitjema T, Disch F, Overtoom TT, et al. Screening family members of patients with hereditary hemorrhagic telangiectasia. Am J Med 1995; 99:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/14\">",
"      Plauchu H, de Chadar&eacute;vian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/15\">",
"      Fuchizaki U, Miyamori H, Kitagawa S, et al. Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Lancet 2003; 362:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/16\">",
"      Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 1998; 158:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/17\">",
"      Krowka MJ. Hepatopulmonary Syndrome and Portopulmonary Hypertension. Curr Treat Options Cardiovasc Med 2002; 4:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/18\">",
"      Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995; 122:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/19\">",
"      Mathur M, Glenn WW. Long-term evaluation of cava-pulmonary artery anastomosis. Surgery 1973; 74:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/20\">",
"      Kim SJ, Bae EJ, Cho DJ, et al. Development of pulmonary arteriovenous fistulas after bidirectional cavopulmonary shunt. Ann Thorac Surg 2000; 70:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/21\">",
"      Pugash RA. Pulmonary arteriovenous malformations: overview and transcatheter embolotherapy. Can Assoc Radiol J 2001; 52:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/22\">",
"      Wong HH, Chan RP, Klatt R, Faughnan ME. Idiopathic pulmonary arteriovenous malformations: clinical and imaging characteristics. Eur Respir J 2011; 38:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/23\">",
"      HALES MR. Multiple small arteriovenous fistulae of the lungs. Am J Pathol 1956; 32:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/24\">",
"      Cottin V, Chinet T, Lavol&eacute; A, et al. Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients. Medicine (Baltimore) 2007; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/25\">",
"      Garcia-Tsao G, Korzenik JR, Young L, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000; 343:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/26\">",
"      STRINGER CJ, STANLEY AL, BATES RC, SUMMERS JE. Pulmonary arteriovenous fistula. Am J Surg 1955; 89:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/27\">",
"      Haitjema TJ, Overtoom TT, Westermann CJ, Lammers JW. Embolisation of pulmonary arteriovenous malformations: results and follow up in 32 patients. Thorax 1995; 50:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/28\">",
"      Faughnan ME, Lui YW, Wirth JA, et al. Diffuse pulmonary arteriovenous malformations: characteristics and prognosis. Chest 2000; 117:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/29\">",
"      Puskas JD, Allen MS, Moncure AC, et al. Pulmonary arteriovenous malformations: therapeutic options. Ann Thorac Surg 1993; 56:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/30\">",
"      Sluiter-Eringa H, Orie NG, Sluiter HJ. Pulmonary arteriovenous fistula. Diagnosis and prognosis in noncomplainant patients. Am Rev Respir Dis 1969; 100:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/31\">",
"      Jaskolka J, Wu L, Chan RP, Faughnan ME. Imaging of hereditary hemorrhagic telangiectasia. AJR Am J Roentgenol 2004; 183:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/32\">",
"      Remy J, Remy-Jardin M, Wattinne L, Deffontaines C. Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment. Radiology 1992; 182:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/33\">",
"      Remy J, Remy-Jardin M, Giraud F, Wattinne L. Angioarchitecture of pulmonary arteriovenous malformations: clinical utility of three-dimensional helical CT. Radiology 1994; 191:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/34\">",
"      Dutton JA, Jackson JE, Hughes JM, et al. Pulmonary arteriovenous malformations: results of treatment with coil embolization in 53 patients. AJR Am J Roentgenol 1995; 165:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/35\">",
"      Terry PB, White RI Jr, Barth KH, et al. Pulmonary arteriovenous malformations. Physiologic observations and results of therapeutic balloon embolization. N Engl J Med 1983; 308:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/36\">",
"      Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/37\">",
"      Shovlin CL, Tighe HC, Davies RJ, et al. Embolisation of pulmonary arteriovenous malformations: no consistent effect on pulmonary artery pressure. Eur Respir J 2008; 32:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/38\">",
"      Sperling DC, Cheitlin M, Sullivan RW, Smith A. Pulmonary arteriovenous fistulas with pulmonary hypertension. Chest 1977; 71:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/39\">",
"      Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003; 40:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/40\">",
"      Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/41\">",
"      Abdalla SA, Gallione CJ, Barst RJ, et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 2004; 23:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/42\">",
"      Whyte MK, Hughes JM, Jackson JE, et al. Cardiopulmonary response to exercise in patients with intrapulmonary vascular shunts. J Appl Physiol 1993; 75:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/43\">",
"      Chilvers ER, Whyte MK, Jackson JE, et al. Effect of percutaneous transcatheter embolization on pulmonary function, right-to-left shunt, and arterial oxygenation in patients with pulmonary arteriovenous malformations. Am Rev Respir Dis 1990; 142:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/44\">",
"      Murphy J, Pierucci P, Chyun D, et al. Results of exercise stress testing in patients with diffuse pulmonary arteriovenous malformations. Pediatr Cardiol 2009; 30:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/45\">",
"      Moussouttas M, Fayad P, Rosenblatt M, et al. Pulmonary arteriovenous malformations: cerebral ischemia and neurologic manifestations. Neurology 2000; 55:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/46\">",
"      Rom&aacute;n G, Fisher M, Perl DP, Poser CM. Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): report of 2 cases and review of the literature. Ann Neurol 1978; 4:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/47\">",
"      White RI Jr, Pollak JS, Wirth JA. Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. J Vasc Interv Radiol 1996; 7:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27656/abstract/48\">",
"      Ference BA, Shannon TM, White RI Jr, et al. Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest 1994; 106:1387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8267 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-4DCBBA35C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27656=[""].join("\n");
var outline_f27_0_27656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1843005\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22399108\">",
"      Imaging findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physiological tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stroke and brain abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hemothorax and hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1843005\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8267\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8267|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/45/27344\" title=\"diagnostic image 1\">",
"      Pulmonary AVM PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/22/3426\" title=\"diagnostic image 2\">",
"      Arteriovenous malformation CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/7/21616\" title=\"diagnostic image 3\">",
"      PAVM angiogram I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8267|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/34/10786\" title=\"picture 1\">",
"      Mucosal telangiectasias in HHT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8267|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/12/12493\" title=\"table 1\">",
"      Clinical features of HHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/26/37291\" title=\"table 2\">",
"      Symptoms of pulmonary AVM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13403\" title=\"table 3\">",
"      Complications of pulmonary AVM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=related_link\">",
"      Etiology and evaluation of hemoptysis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32263?source=related_link\">",
"      Pulmonary arteriovenous malformations: Diagnostic evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_0_27657="DM in graft-versus-host";
var content_f27_0_27657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis-like changes in graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Perimysial perifascicular atrophy.",
"    <br>",
"     (C, D) Muscle infarction.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Allen, JA, Greenberg, SA, Amato, AA. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease. Muscle &amp; Nerve 2009; 40:643. Copyright &copy; 2009. This material was reproduced with permission of John Wiley &amp; Sons.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27657=[""].join("\n");
var outline_f27_0_27657=null;
var title_f27_0_27658="C-reactive protein in cardiovascular disease";
var content_f27_0_27658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   C-reactive protein in cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27658/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27658/contributors\">",
"     David A Morrow, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27658/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27658/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/0/27658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/0/27658/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/0/27658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental and clinical evidence accumulated since 1990 have established inflammatory processes as important contributors to atherogenesis, as well as to the vulnerability of an atherosclerotic lesion to rupture or erosion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon this evidence, protein markers of inflammation have been studied as noninvasive indicators of underlying atherosclerosis in apparently healthy individuals and of the risk of recurrent events in patients with established atherosclerotic vascular disease. The most extensively studied biomarker of inflammation in cardiovascular diseases is C-reactive protein (CRP), for which standardized high-sensitivity assays (hs-CRP) are widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRP is an acute phase protein that is produced predominantly by hepatocytes under the influence of cytokines such as interleukin (IL)-6 and tumor necrosis factor-alpha&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite a lack of specificity for the cause of inflammation, data from more than 30 epidemiologic studies have shown a significant association between elevated serum or plasma concentrations of CRP and the prevalence of underlying atherosclerosis, the risk of recurrent cardiovascular events among patients with established disease, and the incidence of first cardiovascular events among individuals at risk for atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In addition, a number of drugs used in the treatment of cardiovascular disease reduce serum CRP. It is therefore possible that reduced inflammation contributes to the beneficial effects of these medications. However, despite the consistent epidemiological evidence, there is, at present, no established role for routine measurement of hsCRP in patients with cardiovascular disease.",
"   </p>",
"   <p>",
"    These issues as well as the mechanisms of association with cardiovascular risk will be reviewed here. The application of CRP measurement for screening for cardiovascular risk is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=see_link\">",
"     \"Screening for cardiovascular risk with C-reactive protein\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POSSIBLE PATHOGENIC ROLE OF CRP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The participation of inflammatory cells and mediators in atherogenesis and plaque rupture is well established [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether serum CRP is a nonspecific marker that is increased as part of the acute phase response to inflammation or a direct participant in the progression of atherosclerosis and its clinical consequences has been widely discussed and remains an unresolved question, although evidence has mounted that it is not causal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following, earlier observations suggest that there may be a direct effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CRP has been found in atherosclerotic lesions.",
"     </li>",
"     <li>",
"      CRP binds to low density lipoprotein (LDL), allowing LDL to be taken up by macrophages without the need for modification [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recombinant human CRP was infused into seven normal men in whom very high serum CRP concentrations were attained (mean 23.9",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/11\">",
"       11",
"      </a>",
"      ]. The CRP infusion was associated with marked elevations in markers of both inflammation (IL-6, IL-8, and serum amyloid A) and coagulation (von Willebrand factor antigen, prothrombin F1+2, D-dimer, and plasminogen activator inhibitor type 1).",
"     </li>",
"     <li>",
"      In an animal model of increased atherosclerosis, treatment with native CRP increased aortic plaque area [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CRP induces adhesion molecule expression and the production of interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells; these effects might enhance a local inflammatory response within the atherosclerotic plaque by the recruitment of monocytes and lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to potentially promoting atherosclerosis, CRP may also have an adverse effect in myocardial infarction that may be mediated in part by an interaction with complement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The possible role of CRP was directly addressed in a rat model of myocardial infarction in which infused human CRP increased infarct size, an effect that was blocked by pretreatment with a synthetic small-molecule inhibitor of CRP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/18\">",
"     18",
"    </a>",
"    ]. This inhibitor binds to CRP and blocks both CRP-induced complement activation and the interaction of CRP with various ligands found in ischemic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these experimental and clinical observations, other reports have not supported a direct role of CRP in atherogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/5,13,20-26\">",
"     5,13,20-26",
"    </a>",
"    ]. Observations from two large (mendelian randomization) studies suggest that there is not a direct pathogenic role of CRP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of over 50,000 individuals with and without ischemic cardiovascular disease in whom the levels of high-sensitivity CRP and genotype for four CRP polymorphisms were known, the following findings were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The risk of ischemic heart disease was increased significantly in persons who had serum CRP levels above 3",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      as compared with persons with CRP levels below 1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (adjusted hazard ratio [HR] 1.6, 95% CI 1.2-2.1). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CRP in cardiovascular disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Genotype combinations of the four CRP polymorphisms explained a difference in plasma CRP levels of up to 64 percent, resulting in a theoretically predicted increased risk for ischemic heart and cerebrovascular disease of as much as 32 and 25 percent, respectively.",
"     </li>",
"     <li>",
"      Despite the theoretical considerations, none of the genotype combinations were associated with an increased risk of ischemic cardiovascular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar findings were noted in a second report of similar design, which used both genome-wide association study and mendelian randomization techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/26\">",
"       26",
"      </a>",
"      ]. Polymorphisms in five genetic loci strongly associated with CRP levels were identified. However, variants in these CRP loci were not associated with the incidence of coronary heart disease in an analysis of over 28,000 cases and 100,000 controls. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H36#H36\">",
"       \"Glossary of common biostatistical and epidemiological terms\", section on 'Mendelian randomization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We find the results of these last two studies, which suggest that CRP is NOT causative of cardiovascular disease, compelling. Alternative explanations for the strong relationship between elevated CRP and ischemic heart disease include the possibility that CRP is a marker of other factors which promote cardiovascular disease (eg, inflammation), or that ischemic cardiovascular disease increases CRP levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional methods for measuring serum CRP were developed for use in patients with infectious and inflammatory disorders. These assays typically have a detection limit that in the range of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    which is above the concentration observed in most apparently healthy individuals. High sensitivity methods for measurement of CRP (hs-CRP) detect concentrations down to 0.3",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    These assays are necessary for cardiovascular risk stratification, which is based upon discrimination of CRP levels extending below 3",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    value that constitutes an elevation in serum hs-CRP is not clearly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. A statement from the Centers for Disease Control and Prevention and the American Heart Association",
"    <span class=\"nowrap\">",
"     (CDC/AHA)",
"    </span>",
"    reached the following conclusions for the use of serum hs-CRP to estimate cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The average of two assays, fasting or nonfasting, and optimally obtained two weeks apart provide a more stable estimate than a single measurement.",
"     </li>",
"     <li>",
"      For the determination of cardiovascular risk, low, average, and high risk values were defined as &lt;1, 1 to 3, and &gt;3",
"      <span class=\"nowrap\">",
"       mg/L;",
"      </span>",
"      these values correspond to approximate tertiles in the general population. It was suggested that a value above 10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should initiate a search for a source of infection or inflammation. The measurement of hs-CRP should be repeated in two weeks.",
"     </li>",
"     <li>",
"      Among patients with known coronary heart disease (CHD), it was suggested that a value &gt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      is appropriate for predicting outcomes in patients with stable CHD and that a threshold &gt;10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      may be more predictive in patients with an acute coronary syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Variability of measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the precision of the hs-CRP assay is 0.3",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    the",
"    <span class=\"nowrap\">",
"     CDC/AHA",
"    </span>",
"    recommendation of two measurements to confirm a stable value is a reflection of the fact that systemic inflammatory status can fluctuate over time. The variability of CRP measurements is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=see_link&amp;anchor=H3#H3\">",
"     \"Screening for cardiovascular risk with C-reactive protein\", section on 'Variability of measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCREENING FOR CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that elevated serum or plasma CRP is an independent predictor of atherosclerosis among apparently healthy men and women. Among apparently healthy men, the plasma concentration of CRP predicts the long-term risk of a first myocardial infarction, ischemic stroke, or peripheral vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, serum CRP is twofold higher in men with documented coronary heart disease and four-fold higher in those with a myocardial infarction compared to control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/30\">",
"     30",
"    </a>",
"    ]. Measurement of serum CRP may therefore contribute to cardiovascular risk assessment along with traditional cardiovascular risk factors.",
"   </p>",
"   <p>",
"    The possible role of CRP in screening for cardiovascular risk is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=see_link&amp;anchor=H5#H5\">",
"     \"Screening for cardiovascular risk with C-reactive protein\", section on 'Association with established risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CRP IN CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with established cardiovascular disease, the predictive value of CRP for disease severity and prognosis has been studied in a wide variety of settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role in stable coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute phase response appears to be associated with underlying atherosclerosis and has been postulated to reflect the risk of rupture of vulnerable plaque; on the other hand, the acute phase response is not stimulated by transient ischemic episodes alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. As a result, CRP is associated with the risk of future acute events in patients with stable angina, but is only weakly associated with the extent of coronary disease on angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/33,34\">",
"     33,34",
"    </a>",
"    ] and the degree of coronary artery calcification on electron beam CT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\", section on 'Comparison to hsCRP and other biomarkers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with known stable coronary disease, a strong positive correlation between CRP measured at baseline and future acute coronary events has been demonstrated in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/33,36-41\">",
"     33,36-41",
"    </a>",
"    ]. However, results from these studies cannot be directly compared as cut points for CRP levels differed from study to study. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a large study using the above recommendations from the",
"    <span class=\"nowrap\">",
"     CDC/AHA",
"    </span>",
"    to categorize patients as low-, average-, or high-risk (cut points of &lt;1, 1 to 3, and &gt;3",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/4\">",
"     4",
"    </a>",
"    ], 3771 patients with stable coronary artery disease in the PEACE trial were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients had hs-CRP measured at baseline and were followed for outcomes of cardiovascular death, MI or stroke over a mean follow-up of 4.8 years. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Across all measured subgroups, including men and women, patients on or off statin therapy, and patients with or without prior coronary revascularization, higher baseline hs-CRP levels were associated with significantly a higher rate of cardiovascular events compared to those with hs-CRP &lt;1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (hs-CRP 1 to 3",
"      <span class=\"nowrap\">",
"       mg/L:",
"      </span>",
"      adjusted hazard ratio [HR] 1.39, 95% CI 1.06-1.81; hs-CRP &gt;3",
"      <span class=\"nowrap\">",
"       mg/L:",
"      </span>",
"      adjusted HR 1.52; 95% CI 1.15-2.02).",
"     </li>",
"     <li>",
"      An elevated hs-CRP was predictive of the development of heart failure and new diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the association with cardiovascular outcomes, serum CRP may predict coronary disease progression. Such an association was suggested in a report of 124 patients with chronic stable angina awaiting elective PCI (mean time on the waiting list 4.8 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/42\">",
"     42",
"    </a>",
"    ]. Rapid coronary stenosis progression, which occurred in 35 patients (28 percent), was defined as a &ge;10 percent diameter reduction of a preexisting &ge;50 percent stenosis, a &ge;30 percent diameter reduction of a &lt;50 percent stenosis, development of a new &ge;30 percent narrowing, or progression of any stenosis to total vessel occlusion. After multivariate adjustment, elevated serum CRP was an independent predictor of rapid progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Role in plaque rupture and ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary pathophysiologic event in an acute coronary syndrome (ACS) is thought to be plaque rupture followed by thrombus formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sequence of events leading to plaque rupture and the factors that predispose to these events are incompletely understood. The association between ACS and elevated serum concentrations of acute phase reactants, such as CRP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/31,38,43,44\">",
"     31,38,43,44",
"    </a>",
"    ], SAA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], and IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/45\">",
"     45",
"    </a>",
"    ], suggests that chronic inflammation of the coronary arterial wall may play an important role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The elevated levels of acute phase reactants in patients with an ACS appear to be a marker of widespread underlying vascular inflammation and hyperresponsiveness of the inflammatory system to even small stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/46\">",
"     46",
"    </a>",
"    ]. They are not the result of localized plaque rupture alone.",
"   </p>",
"   <p>",
"    The following observations from several studies are consistent with this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a non-ST elevation ACS had higher serum CRP concentrations than those with stable angina [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients presenting with preinfarction unstable angina had much higher serum concentrations of CRP, SAA, and IL-6 than those presenting with an unheralded MI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with unstable angina had a significant reduction in neutrophil myeloperoxidase content (a measure of inflammation) in the left coronary circulation (the great cardiac vein), even when the culprit lesion was in the right coronary artery, suggesting diffuse inflammation in the coronary arteries rather than inflammation limited to the culprit vessel [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/47\">",
"       47",
"      </a>",
"      ]. Such changes were not seen in patients with patients with stable angina and multiple stenoses or those with variant angina.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has also been suggested that elevated serum CRP is associated with plaque vulnerability and coronary disease activity. Consistent with this hypothesis is the observation that, among patients with acute coronary syndromes without ST-segment elevation, serum CRP levels correlated with the number of complex angiographic stenoses but not with smooth lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prognosis after non-ST elevation ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased CRP concentrations at admission and prior to hospital discharge are a marker for a worse short- and long-term prognosis in patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/43,48-53\">",
"     43,48-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations illustrate the potential prognostic importance of serum CRP at enrollment in patients with a non-ST elevation ACS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the GUSTO IV ACS trial, over 7000 patients were stratified by quartiles of CRP and by quartiles of troponin T [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/53\">",
"       53",
"      </a>",
"      ]. The 30-day mortality rate increased from 2 to 6.3 percent from the first to fourth quartiles of CRP; however, there was no correlation between quartile of CRP and rate of MI at 30 days. CRP and troponin T had independent and complementary prognostic significance; the mortality rate at 30 days ranged from 0.3 to 9.1 percent for patients in the lowest to the highest quartile of both markers.",
"      <br/>",
"      <br/>",
"      In addition to supporting the complementary predictive value of CRP and troponins, this study confirmed prior observations that, when measured very early after ACS, CRP appears to be a stronger predictor of death than nonfatal recurrent ischemic events.",
"     </li>",
"     <li>",
"      In the PROVE IT-TIMI 22 trial, among 4162 patients stabilized after ACS, those with hsCRP &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      were at a nearly twofold higher risk of developing new or worsening heart failure during a mean follow-up of 24 months [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar predictive value of serum CRP and its interaction with serum troponin T were noted In the smaller TIMI 11A (",
"      <a class=\"graphic graphic_figure graphicRef81008 \" href=\"UTD.htm?11/3/11326\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/48\">",
"       48",
"      </a>",
"      ] and FRISC trials (",
"      <a class=\"graphic graphic_figure graphicRef58001 \" href=\"UTD.htm?12/34/12847\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum CRP is an independent predictor of short- and long-term mortality in patients with an ACS who undergo early revascularization. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Predictor of adverse events after PCI'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum CRP may remain elevated for a prolonged period after symptoms abate. Patients with elevated serum CRP at discharge are at greater risk for recurrent symptoms or a new MI (in one report, 69 versus 15 percent in patients with normal serum CRP at discharge) (",
"    <a class=\"graphic graphic_figure graphicRef65599 \" href=\"UTD.htm?22/48/23310\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some, but not all, studies have found that serum CRP is more useful for predicting intermediate to long-term outcomes than the risk of recurrent events in-hospital. In a series of 447 patients with unstable angina, cardiac troponin T but not serum CRP was associated with the risk of death or recurrent ischemic events in the first 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/51\">",
"     51",
"    </a>",
"    ]. In contrast, both markers predicted a higher risk of death or MI by 30 days and six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prognosis after acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have found that serum CRP and SAA predict the risk of a recurrent in-hospital cardiac event [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/38\">",
"     38",
"    </a>",
"    ] or 30-day or long-term mortality after a myocardial infarction (MI) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. However, other reports have not found such a relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. The range of findings is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 861 consecutive patients admitted within six hours of the onset of an acute ST-elevation MI treated with thrombolysis in whom high sensitivity-CRP (hs-CRP) levels were checked serially (at presentation and at 24, 48, and 72 hours following presentation), higher hs-CRP levels at presentation were associated with a significantly greater risk of recurrent nonfatal MI and cardiac death (relative risk 2.8 and 2.1, respectively) over an average follow-up of 3.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in two series of 483 and 729 patients with acute MI in whom CRP was measured within six hours of symptom onset or at presentation, there was no relationship between elevated CRP and the risk of death or death or nonfatal MI in the following 30 days [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/60\">",
"       60",
"      </a>",
"      ] or in mortality at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevations in serum CRP early after acute MI may reflect the extent of and reaction to myocardial injury. This possibility suggests that, if serum CRP is to be used for long-term cardiovascular assessment, the measurement should be delayed for at least four to six weeks after an infarction to permit resolution of the acute phase reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of such a delay was assessed in the THROMBO trial in which serum CRP and SAA were measured in 1045 patients two months after an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/58\">",
"     58",
"    </a>",
"    ]. Although patients in the highest quartile of CRP and SAA concentrations had an increased rate of coronary events compared to those in the lower quartiles, neither CRP nor SAA were independent markers for recurrent events on multivariate analysis, that included gender, diabetes, prior MI, heart failure, ejection fraction, and location of the MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Predictor of recurrent ischemia after CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated preoperative serum CRP may be a risk indicator for recurrent ischemic events after coronary artery bypass grafting (CABG). This was illustrated in a report of 86 patients who underwent CABG for stable or unstable angina; after a mean follow-up of 3.6 years, a preoperative serum CRP &ge;3",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    when compared to lower values, was associated with a significantly higher incidence of new ischemic events (25 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Predictor of adverse events after PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preprocedural activation of inflammatory cells may play a role in the modulation of the vessel wall response to injury after elective percutaneous coronary intervention (PCI) with or without stenting. A prognostic correlation after angioplasty alone was seen in a series of 121 patients with stable or unstable angina; a high preprocedural serum CRP concentration (&gt;3",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    was a powerful predictor of adverse events, including both intraprocedural and in-hospital complications (22 versus 0 percent for normal CRP levels) and clinical restenosis at one year (63 versus 27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated preprocedural CRP levels are also predictive of a worse outcome after elective or urgent coronary artery stenting, which itself can elicit an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/65\">",
"     65",
"    </a>",
"    ]. The following findings have been noted in different reports in patients with higher values of preprocedural CRP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2.5-fold increase in the rate of death or MI at 30 days, which could be combined with other established predictors, especially the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      lesion score (",
"      <a class=\"graphic graphic_figure graphicRef56373 \" href=\"UTD.htm?3/7/3188\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An approximately fourfold increase in mortality in-hospital and at 20 months in patients with an ACS undergoing early revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At three years after successful stenting, an approximately five-fold increase in the combined end point of death, MI, or unstable angina and a marked increase in the rate of progression of untreated lesions to significant stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are conflicting data as to whether there is [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/68\">",
"       68",
"      </a>",
"      ] or is not [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/69,70\">",
"       69,70",
"      </a>",
"      ] a higher incidence of restenosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrence of ischemic symptoms. The more consistent relationship between CRP and the risk of spontaneous new plaque rupture supports the hypothesis that the risk attributable to inflammation is related to a diffuse process rather than focal inflammation at the location of the culprit for a prior event (ie, promoting restenosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Role in plaque rupture and ACS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with elevated serum CRP prior to stenting, statins appear to reduce the risk of adverse cardiac events. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Statins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Predictor in heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data have been limited on the predictive value of serum CRP in patients with heart failure (HF) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. This issue was addressed in a post hoc analysis from the Val-HeFT trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    therapy in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/72\">",
"     72",
"    </a>",
"    ]. The median serum CRP was higher in patients with HF compared to the general population and the cumulative likelihood of death or a first morbid event increased progressively with quartiles of serum CRP (eg, the adjusted hazard ratio for mortality was 1.53 in the highest compared to the lowest quartile for serum CRP). At one year, serum CRP was stable in the placebo group but fell in patients receiving valsartan who were not receiving an ACE inhibitor but not in those who were. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Predictor of sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible predictive value of serum CRP for sudden cardiac death (SCD) in apparently healthy men was evaluated in a nested case-control analysis from the Physicians' Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/74\">",
"     74",
"    </a>",
"    ]. At 17-year follow-up, serum CRP (measured on a single sample at baseline) was significantly associated with SCD; this effect was primarily seen in men in the highest quartile of CRP (relative risk 2.78 compared to the lowest quartile). In a cohort of 235 patients who received an implantable cardioverter-defibrillator (ICD) for primary prevention of SCD, significantly higher baseline CRP levels were noted among those who subsequently experienced an appropriate ICD therapy or cardiac death (5.4 versus 2.7",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    in those without an event) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Predictor in cerebrovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to its role in coronary heart disease, CRP is an independent marker for the development and progression of early carotid atherosclerotic disease (but not the extent of disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/76\">",
"     76",
"    </a>",
"    ]; the risk of ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/77\">",
"     77",
"    </a>",
"    ]; and prognosis after a stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. In one report, for example, an increase in serum CRP between 12 and 24 hours after symptom onset in patients with a first ischemic stroke predicted an unfavorable outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/80\">",
"     80",
"    </a>",
"    ]. In an observational study of 6430 participants followed for an average of 8.2 years, it was shown that although CRP levels are associated with stroke risk, their use in the assessment of individual stroke risk was limited when other baseline characteristics were taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Predictor of cardiac allograft survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant coronary artery disease is the leading cause of death or retransplantation in cardiac transplant recipients surviving more than six months. Elevated serum CRP appears to be a predictor for transplant vasculopathy and allograft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link\">",
"     \"Prognosis after cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=see_link\">",
"     \"Pathogenesis of and risk factors for cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Risk stratification in peripheral artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with peripheral artery disease often have coronary artery disease, which increases the risk of a cardiac event after vascular surgery. A number of noninvasive tests are useful for preoperative risk stratification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H27#H27\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Noninvasive cardiac testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preoperative measurement of CRP may improve long-term prognostic assessment, as suggested in a study of 51 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/84\">",
"     84",
"    </a>",
"    ]. During a follow-up of 24 months, 34 percent had a fatal or nonfatal MI. With a multivariate analysis, which included a history of coronary disease, the Eagle score, and other cardiovascular risk factors, only a CRP value &gt;9",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    was significantly associated with an MI. Studies with larger numbers of patients are necessary to confirm this observation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H23#H23\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Eagle criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Role in AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inflammatory process may play a role in the genesis of atrial fibrillation (AF), as suggested by the high incidence of AF after cardiac surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In several observational studies, elevated serum levels of CRP have been described in the following populations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with recent atrial arrhythmias compared to controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients who later develop new onset AF [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with AF who fail cardioversion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients who are likely to have recurrent AF after cardioversion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether inflammation plays a direct causal role in the development and perpetuation of AF, or it is a marker for other conditions that predispose to AF remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H26#H26\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Inflammation and infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Role in hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible predictive value of serum CRP for the development of hypertension was evaluated in an analysis from the Women's Health Study of over 20,000 female health professionals in the United States with a baseline blood pressure",
"    <span class=\"nowrap\">",
"     &lt;140/90",
"    </span>",
"    mmHg and no history of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/90\">",
"     90",
"    </a>",
"    ]. Serum CRP was measured at baseline and the women followed for a median of 7.8 years; hypertension developed in 11.5 percent. There was a progressive increase in the rate of developing hypertension with increasing values of serum CRP (relative risk after adjusting for coronary risk factors 1.52 for the highest compared to the lowest group [serum CRP &gt;3.5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    versus &lt;0.4",
"    <span class=\"nowrap\">",
"     mg/L]).",
"    </span>",
"   </p>",
"   <p>",
"    This",
"    observation suggests a role for inflammation in the pathogenesis of hypertension. The association could be related in part to an association between serum CRP and the metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/91\">",
"     91",
"    </a>",
"    ]. It is also possible that CRP may directly contribute by reducing nitric oxide synthesis in endothelial cells, leading to increased vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     EFFECT OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs used in the treatment of cardiovascular disease and certain dietary modifications reduce serum CRP. It is therefore possible that reduced inflammation contributes to the beneficial effects of these medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Effect on CRP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple statins significantly decrease serum CRP in patients with hyperlipidemia; this decrease appears to be independent of reductions in LDL-cholesterol (LDL-C) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. The effect of statins on CRP may be mediated in part by reduced monocyte expression of IL-6 and tumor necrosis factor-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/97,98\">",
"     97,98",
"    </a>",
"    ] or by direct suppression of CRP gene transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy with a statin reduces serum CRP both after an ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/40,95,100,101\">",
"     40,95,100,101",
"    </a>",
"    ] and when given for primary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/96,102\">",
"     96,102",
"    </a>",
"    ]. The fall in serum CRP is seen as early as 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/94\">",
"     94",
"    </a>",
"    ]. In a literature review of thirteen controlled trials, statins reduced CRP levels by 13 to 50 percent compared to placebo; there was no advantage of one statin over another in five studies making direct comparisons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/100\">",
"     100",
"    </a>",
"    ]. In phase Z of the A to Z trial, more intensive statin therapy was associated with a modestly greater reduction in CRP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Reduction in coronary risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observations that statin therapy reduces serum CRP and that serum CRP is correlated with cardiovascular risk raises the possibility that the risk reduction with statin therapy may be attributed, at least in part, to antiinflammatory effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several clinical studies have provided supportive evidence for this concept:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients undergoing PCI, observational studies suggest that benefit from statin therapy is principally seen in those with a serum CRP in the upper 25 to 50 percent of the study population [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/103,104\">",
"       103,104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the",
"      <span class=\"nowrap\">",
"       AFCAPS/TexCAPS",
"      </span>",
"      trial of primary prevention,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      reduced CRP by almost 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/102\">",
"       102",
"      </a>",
"      ]. A significant reduction in coronary events was seen, not only in patients with an elevated total cholesterol-to-HDL cholesterol ratio, but also in those with an elevated serum CRP but no elevation in lipid ratio. Modeling of the",
"      <span class=\"nowrap\">",
"       AFCAPS/TexCAPS",
"      </span>",
"      data suggested that 58-year-old men or women with a serum LDL-C concentration below 149",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      might benefit from statin therapy if they have a serum CRP concentration &ge;1.6",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Phase Z of the A to Z trial, 4497 patients with an ACS were randomly assigned to aggressive statin therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one month, then 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or to delayed conservative statin therapy (placebo for four months, then simvastatin 20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/100\">",
"       100",
"      </a>",
"      ]. At one month, patients in the aggressive therapy arm (taking 40 mg of simvastatin) had a marked reduction in LDL-C concentration, but",
"      <strong>",
"       no",
"      </strong>",
"      reduction in the incidence of the primary end point (cardiovascular death, MI, readmission for ACS, or stroke). Instead, the benefit seen in Phase Z corresponded to the timing of a reduction in serum CRP seen when the dose of simvastatin was increased from 40 to 80",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H40#H40\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Phase Z of the A to Z trial'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Further assessment of patients in the Phase Z of the A to Z trial showed that levels of hsCRP at 30 days and four months after acute coronary syndrome are independently associated with long-term survival. This study also showed that patients treated with more aggressive statin therapy are more likely to achieve lower levels of hsCRP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/106\">",
"       106",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with hsCRP &gt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      at 30 days had significantly higher two-year mortality rates than those with hsCRP 1 to 3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      or hsCRP &lt;1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (6.1 versus 3.7 versus 1.6 percent), and results were similar with hsCRP measured at four months. Patients allocated to early intensive statin therapy were significantly more likely to achieve hsCRP levels &lt;1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      at 30 days and four months.",
"     </li>",
"     <li>",
"      In the PROVE IT-TIMI 22 trial, 4162 patients with an ACS were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/101\">",
"       101",
"      </a>",
"      ]. There were significant reductions in serum CRP by 30 days in both treatment arms. There was only a limited correlation between the achieved levels of CRP and the achieved levels of LDL-C; less than 3 percent of the variance in achieved serum CRP was explained by the variance in achieved LDL-C. Despite the nearly complete independence of these two factors, there was also a linear relationship between the levels of CRP achieved after statin therapy and the risk of recurrent MI or coronary death. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H37#H37\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'PROVE IT-TIMI 22 trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the REVERSAL trial, intravascular ultrasonography was used to assess atherosclerosis progression in 502 patients with angiographic coronary disease who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/107\">",
"       107",
"      </a>",
"      ]. Serum CRP was significantly reduced by statin therapy; the reduction in CRP was only weakly correlated with the reduction in LDL-C. The rate of progression of atherosclerosis by intravascular ultrasonography was significantly correlated with the reductions in LDL-C, CRP, apolipoprotein B-100, and non-HDL cholesterol. After adjustment for the reduction in lipid levels, the decrease in serum CRP was still significantly correlated with atherosclerosis progression, with regression observed in those with the greatest fall in serum CRP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'REVERSAL trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The JUPITER trial, which randomly assigned patients with an LDL-C level below 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and a C-reactive protein level of at least 2.0",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      20 mg daily or placebo and demonstrated better outcomes in the treated group, is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'JUPITER trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the aggregate, these studies support the hypothesis that lowering serum CRP and LDL-C should be \"dual\" goals of statin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/108\">",
"     108",
"    </a>",
"    ]. Prospective randomized trials are necessary to evaluate this hypothesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    does not reduce serum CRP in apparently healthy men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/109\">",
"     109",
"    </a>",
"    ], serum CRP appears to influence the reduction in the relative risk of vascular disease induced by aspirin. In a report of healthy men from the Physician's Health Study, the risk reduction with aspirin was much greater in those in the upper quartile of serum CRP compared to the lower quartile (56 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This observation suggests that the cardiovascular benefit associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy may be mediated by its antiinflammatory as well as its antiplatelet activity. This hypothesis is supported by data from other reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of patients with stable angina found that, compared to placebo, six weeks of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy reduced elevated levels of CRP and proinflammatory cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of patients presenting with a non-ST elevation ACS, prior",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use attenuated the prognostic significance of CRP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     Abciximab",
"    </a>",
"    reduces the risk of an acute ischemic event after percutaneous coronary intervention. It is possible that an antiinflammatory effect contributes to the benefit. In a study of 160 patients, abciximab ameliorated the transient increases in serum CRP, interleukin-6, and tumor necrosis factor alpha induced by angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    therapy reduce serum CRP concentrations in patients with or without type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/113-116\">",
"     113-116",
"    </a>",
"    ]. This effect is independent of glycemic control and is not seen with a sulfonylurea despite a similar improvement in glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H17#H17\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Thiazolidinediones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of the effect of thiazolidinediones on serum CRP was illustrated in the PIOSTAT trial of 125 nondiabetic subjects with cardiovascular disease and elevated serum CRP who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    (45",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus placebo, or a",
"    <span class=\"nowrap\">",
"     pioglitazone/simvastatin",
"    </span>",
"    combination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/116\">",
"     116",
"    </a>",
"    ]. At 12 weeks, serum CRP fell significantly with monotherapy with pioglitazone or simvastatin (3.64 to 2.48 and 3.26 to 2.81",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    respectively), and the combination regimen had an additive effect (3.49 to 2.06",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of beta blockers on serum CRP was examined in a study of 333 patients with stable angina undergoing coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/117\">",
"     117",
"    </a>",
"    ]. After adjusting for other clinical predictors of serum CRP and excluding patients with contraindications to beta blocker use, beta blocker therapy was associated with a significant 31 percent relative reduction in serum CRP. The clinical significance of this observation is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Hormone replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormone replacement therapy (HRT) raises serum CRP in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/118-120\">",
"     118-120",
"    </a>",
"    ]. In the PEPI trial, for example, serum CRP concentrations were measured in 365 women at baseline, 12, and 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/120\">",
"     120",
"    </a>",
"    ]. Compared to placebo, all preparations of HRT were associated with an increase in serum CRP, which occurred primarily during the first year of treatment; final concentrations of CRP were 85 percent higher than baseline in the HRT group. This observation suggests a proinflammatory effect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/118-120\">",
"     118-120",
"    </a>",
"    ], although HRT does not appear to increase serum IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the elevation in serum CRP induced by HRT has any clinical significance is not known. Although it had been thought that HRT was cardioprotective, this hypothesis was not confirmed in the Women's Health Initiative (WHI), mostly of primary prevention, and the HERS trials of secondary prevention. Estrogen-progestin replacement had no cardioprotective effect and may have produced harm. In a report from the WHI observational study, use or nonuse of HRT was less predictive of cardiovascular risk than either serum CRP or IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Dietary modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific changes in diet may reduce serum CRP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 55 healthy adults were assigned to one of three groups: a diet low in saturated fat, the same diet with statin therapy, or the same diet plus increases in plant sterols, viscous fiber, soy protein, and nuts [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/121\">",
"       121",
"      </a>",
"      ]. After one month, serum CRP decreased in all three groups; the reduction was significantly greater with a statin or the plant sterol diet than with the low saturated fat diet alone (33 and 28 versus 10 percent).",
"     </li>",
"     <li>",
"      In another randomized trial in 78 severely obese patients (86 percent with either diabetes or the metabolic syndrome), both a low carbohydrate and a conventional calorie- and fat-restricted diet caused a modest decrease in serum CRP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/122\">",
"       122",
"      </a>",
"      ]. However, in patients with a high baseline serum CRP (&gt;3",
"      <span class=\"nowrap\">",
"       mg/L),",
"      </span>",
"      there was a significant decrease in serum CRP with the low carbohydrate but not the conventional diet.",
"     </li>",
"     <li>",
"      In a randomized, crossover trial of 35 healthy adults who received two diets supplemented with 30 grams of fiber per day for three weeks, the mean CRP fell significantly from 4.4 to 3.7",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2003 scientific statement on inflammatory markers from the Center for Disease Control and Prevention and the American Heart Association included the following conclusions concerning the use of hs-CRP in patients with stable CAD or ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based principally on analytic properties that influence the reliability of testing, hs-CRP was considered the inflammatory marker most useful for clinical practice. Values should be reported in",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"     </li>",
"     <li>",
"      Among patients with known CHD, it was suggested that a value &gt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      is appropriate for predicting outcomes in patients with stable CHD and that a threshold &gt;10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      may be more predictive in patients with an acute coronary syndrome.",
"     </li>",
"     <li>",
"      hs-CRP may be useful as an independent marker of prognosis in patients with stable CHD or an ACS. However, there is at present insufficient evidence to recommend that CRP determine the application of specific therapies for acute management of ACS or for secondary prevention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following additional considerations may be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with known CHD and hs-CRP&lt;1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      on contemporary medical therapy, including statins, appear to be at particularly low risk.",
"     </li>",
"     <li>",
"      The optimal timing of measurement of hs-CRP in patients with an ACS is uncertain. However, if used for early risk stratification in conjunction with serum troponins, values obtained as soon as possible after presentation are less likely to be influenced by the extent of necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/124\">",
"       124",
"      </a>",
"      ]. When used for assessment of long-term cardiovascular risk, measurement at least four to six weeks after a myocardial infarction appears preferable to permit resolution of the acute phase reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/0/27658/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although several pharmacologic agents are known to lower CRP, including statins and thiazolidinediones, the appropriate therapeutic response to elevated levels of hs-CRP in patients with an ACS or stable CHD is not clearly defined. Based upon the higher absolute risk associated with elevated CRP, there is potential for greater absolute risk reductions with established preventive interventions. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, we sometimes use hs-CRP in conjunction with LDL-C to titrate the dose of statin therapy in patients with established CHD to achieve both an optimal LDL-C &lt;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and, ideally, hs-CRP &lt;1",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/1\">",
"      Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/2\">",
"      Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/3\">",
"      Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982; 389:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/4\">",
"      Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/5\">",
"      Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/6\">",
"      Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/7\">",
"      Nilsson J. CRP--marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005; 25:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/8\">",
"      Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/9\">",
"      Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/10\">",
"      Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/11\">",
"      Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/12\">",
"      Schwedler SB, Amann K, Wernicke K, et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/13\">",
"      Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/14\">",
"      Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/15\">",
"      Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/16\">",
"      Lagrand WK, Niessen HW, Wolbink GJ, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/17\">",
"      Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/18\">",
"      Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/19\">",
"      Kitsis RN, Jialal I. Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med 2006; 355:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/20\">",
"      Clapp BR, Hirschfield GM, Storry C, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005; 111:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/21\">",
"      Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vasc Biol 2004; 24:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/22\">",
"      Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005; 25:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/23\">",
"      Pepys MB, Hawkins PN, Kahan MC, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 2005; 97:e97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/24\">",
"      Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. PLoS One 2008; 3:e1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/25\">",
"      Lawlor DA, Harbord RM, Timpson NJ, et al. The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS One 2008; 3:e3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/26\">",
"      Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/27\">",
"      Schunkert H, Samani NJ. Elevated C-reactive protein in atherosclerosis--chicken or egg? N Engl J Med 2008; 359:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/28\">",
"      Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/29\">",
"      Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/30\">",
"      Anderson JL, Carlquist JF, Muhlestein JB, et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/31\">",
"      Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in \"active\" coronary artery disease. Am J Cardiol 1990; 65:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/32\">",
"      Liuzzo G, Biasucci LM, Rebuzzi AG, et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996; 94:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/33\">",
"      Zebrack JS, Muhlestein JB, Horne BD, et al. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/34\">",
"      Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/35\">",
"      Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006; 113:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/36\">",
"      Bogaty P, Poirier P, Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001; 103:3062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/37\">",
"      Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/38\">",
"      Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000; 140:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/39\">",
"      Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/40\">",
"      Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/41\">",
"      Arroyo-Espliguero R, Avanzas P, Cos&iacute;n-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004; 25:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/42\">",
"      Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/43\">",
"      Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/44\">",
"      Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999; 34:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/45\">",
"      Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/46\">",
"      Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/47\">",
"      Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/48\">",
"      Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/49\">",
"      Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96:4204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/50\">",
"      Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/51\">",
"      Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/52\">",
"      Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/53\">",
"      James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/54\">",
"      Scirica BM, Cannon CP, Sabatine MS, et al. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem 2009; 55:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/55\">",
"      Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006; 47:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/56\">",
"      Makrygiannis SS, Ampartzidou OS, Zairis MN, et al. Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction. Am J Cardiol 2013; 111:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/57\">",
"      Lim P, Moutereau S, Simon T, et al. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]). Am J Cardiol 2013; 111:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/58\">",
"      Harb TS, Zareba W, Moss AJ, et al. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol 2002; 89:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/59\">",
"      Zebrack JS, Anderson JL, Maycock CA, et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002; 89:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/60\">",
"      Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/61\">",
"      Nikfardjam M, M&uuml;llner M, Schreiber W, et al. The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J Intern Med 2000; 247:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/62\">",
"      Zebrack JS, Anderson JL. Should C-reactive protein be measured routinely during acute myocardial infarction? Am J Med 2003; 115:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/63\">",
"      Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999; 84:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/64\">",
"      Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/65\">",
"      Saleh N, Svane B, Jensen J, et al. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris. Am Heart J 2005; 149:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/66\">",
"      Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/67\">",
"      Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/68\">",
"      Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/69\">",
"      Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002; 40:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/70\">",
"      de Winter RJ, Koch KT, van Straalen JP, et al. C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003; 115:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/71\">",
"      Morrow DA. Preprocedural C-reactive protein for risk prediction before percutaneous coronary intervention (PCI): a US perspective. Clin Chem 2004; 50:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/72\">",
"      Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/73\">",
"      Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005; 26:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/74\">",
"      Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/75\">",
"      Wu KC, Gerstenblith G, Guallar E, et al. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging 2012; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/76\">",
"      Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001; 104:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/77\">",
"      Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 2000; 20:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/78\">",
"      Muir KW, Weir CJ, Alwan W, et al. C-reactive protein and outcome after ischemic stroke. Stroke 1999; 30:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/79\">",
"      Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/80\">",
"      Winbeck K, Poppert H, Etgen T, et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002; 33:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/81\">",
"      Bos MJ, Schipper CM, Koudstaal PJ, et al. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation 2006; 114:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/82\">",
"      Eisenberg MS, Chen HJ, Warshofsky MK, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000; 102:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/83\">",
"      Labarrere CA, Lee JB, Nelson DR, et al. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 2002; 360:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/84\">",
"      Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002; 105:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/85\">",
"      Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/86\">",
"      Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/87\">",
"      Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004; 94:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/88\">",
"      Malouf JF, Kanagala R, Al Atawi FO, et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005; 46:1284.",
"     </a>",
"    </li>",
"    <li>",
"     Am J Cardiol 2007; 99:1941.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/90\">",
"      Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/91\">",
"      Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/92\">",
"      Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/93\">",
"      Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/94\">",
"      Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/95\">",
"      Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/96\">",
"      Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/97\">",
"      Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/98\">",
"      Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/99\">",
"      Kleemann R, Verschuren L, de Rooij BJ, et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004; 103:4188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/100\">",
"      de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/101\">",
"      Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/102\">",
"      Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/103\">",
"      Walter DH, Fichtlscherer S, Britten MB, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/104\">",
"      Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/105\">",
"      Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002; 40:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/106\">",
"      Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/107\">",
"      Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/108\">",
"      Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol &lt;70 mg/dl and C-reactive protein &lt;2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005; 45:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/109\">",
"      Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001; 37:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/110\">",
"      Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/111\">",
"      Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001; 37:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/112\">",
"      Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/113\">",
"      Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/114\">",
"      Pf&uuml;tzner A, Marx N, L&uuml;bben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/115\">",
"      Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/116\">",
"      Hanefeld M, Marx N, Pf&uuml;tzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/117\">",
"      Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 2002; 112:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/118\">",
"      Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/119\">",
"      Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/120\">",
"      Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/121\">",
"      Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/122\">",
"      Seshadri P, Iqbal N, Stern L, et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med 2004; 117:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/123\">",
"      King DE, Egan BM, Woolson RF, et al. Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. Arch Intern Med 2007; 167:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/0/27658/abstract/124\">",
"      de Winter RJ, Fischer J, Bholasingh R, et al. C-Reactive protein and cardiac troponin T in risk stratification: differences in optimal timing of tests early after the onset of chest pain. Clin Chem 2000; 46:1597.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1484 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27658=[""].join("\n");
var outline_f27_0_27658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POSSIBLE PATHOGENIC ROLE OF CRP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Variability of measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCREENING FOR CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CRP IN CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role in stable coronary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Role in plaque rupture and ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prognosis after non-ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prognosis after acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Predictor of recurrent ischemia after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Predictor of adverse events after PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Predictor in heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Predictor of sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Predictor in cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Predictor of cardiac allograft survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Risk stratification in peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Role in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Role in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EFFECT OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Effect on CRP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Reduction in coronary risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Hormone replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Dietary modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1484\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1484|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/3/11326\" title=\"figure 1\">",
"      CRP troponin mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/34/12847\" title=\"figure 2\">",
"      CRP troponin non ST ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/48/23310\" title=\"figure 3\">",
"      Discharge CRP levels outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/7/3188\" title=\"figure 4\">",
"      CRP levels outcome stenting",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=related_link\">",
"      Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=related_link\">",
"      Pathology and pathogenesis of the vulnerable plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_0_27659="Indications for colonoscopy";
var content_f27_0_27659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for colonoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Signs/symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower gastrointestinal bleeding and unexplained iron deficiency anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower gastrointestinal symptoms (eg, chronic diarrhea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Screening/surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon polyp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Therapeutic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polypectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localization of lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign body removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompression of sigmoid volvulus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompression of colonic pseudo-obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Balloon dilation of strictures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palliative treatment of bleeding or stenosed neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placement of percutaneous endoscopic cecostomy tube",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27659=[""].join("\n");
var outline_f27_0_27659=null;
var title_f27_0_27660="Phase II trials cispl comb";
var content_f27_0_27660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phase II trials of older combinations of cisplatin with bleomycin, vinca alkaloids, or etoposide in locally advanced or metastatic esophageal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Reference",
"      </td>",
"      <td class=\"subtitle1\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\">",
"       Histology",
"      </td>",
"      <td class=\"subtitle1\">",
"       RR (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       OS (months)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Cisplatin",
"       </p>",
"       <p>",
"        Bleomycin",
"       </p>",
"      </td>",
"      <td>",
"       Coonley, C; 1984",
"      </td>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       SCC",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Cisplatin",
"       </p>",
"       <p>",
"        Bleomycin",
"       </p>",
"      </td>",
"      <td>",
"       Marcuello, E; 1988",
"      </td>",
"      <td>",
"       34",
"      </td>",
"      <td>",
"       SCC",
"      </td>",
"      <td>",
"       52",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Cisplatin",
"       </p>",
"       <p>",
"        Vindesine",
"       </p>",
"      </td>",
"      <td>",
"       Iizuka, T; 1991",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       SCC",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       5.5 - 7.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Cisplatin",
"       </p>",
"       <p>",
"        Bleomycin",
"       </p>",
"       <p>",
"        Vindesine",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Dinwoodie, W; 1986",
"       </p>",
"       <p>",
"        Kelsen, D; 1983",
"       </p>",
"      </td>",
"      <td>",
"       98",
"      </td>",
"      <td>",
"       SCC",
"      </td>",
"      <td>",
"       45",
"      </td>",
"      <td>",
"       3.2 - 7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Cisplatin",
"       </p>",
"       <p>",
"        Etoposide",
"       </p>",
"      </td>",
"      <td>",
"       Kok, T; 1996",
"      </td>",
"      <td>",
"       73",
"      </td>",
"      <td>",
"       SCC",
"      </td>",
"      <td>",
"       48",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Cisplatin",
"       </p>",
"       <p>",
"        Etoposide",
"       </p>",
"      </td>",
"      <td>",
"       Spirinodinis, C; 1996",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       AC",
"      </td>",
"      <td>",
"       48",
"      </td>",
"      <td>",
"       9.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Cisplatin",
"       </p>",
"       <p>",
"        Vinorelbine",
"       </p>",
"      </td>",
"      <td>",
"       Conroy, T; 2002",
"      </td>",
"      <td>",
"       71",
"      </td>",
"      <td>",
"       SCC",
"      </td>",
"      <td>",
"       34",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N: number of patients; RR: response rate; OS: median overall survival time; SCC: squamous cell carcinoma; AC: adenocarcinoma; NA: not available.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Fidias, P, El-Karak, FR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27660=[""].join("\n");
var outline_f27_0_27660=null;
var title_f27_0_27661="GA by crown chin length";
var content_f27_0_27661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gestational age by crown chin length",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Gestational age",
"      </td>",
"      <td class=\"subtitle1\">",
"       2.5th percentile",
"      </td>",
"      <td class=\"subtitle1\">",
"       50th percentile",
"      </td>",
"      <td class=\"subtitle1\">",
"       97.5th percentile",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 wk 0 days",
"      </td>",
"      <td>",
"       12.1",
"      </td>",
"      <td>",
"       17.2",
"      </td>",
"      <td>",
"       22.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 wk 1 days",
"      </td>",
"      <td>",
"       12.7",
"      </td>",
"      <td>",
"       17.8",
"      </td>",
"      <td>",
"       23.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 wk 2 days",
"      </td>",
"      <td>",
"       13.4",
"      </td>",
"      <td>",
"       18.5",
"      </td>",
"      <td>",
"       23.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 wk 3 days",
"      </td>",
"      <td>",
"       14.1",
"      </td>",
"      <td>",
"       19.2",
"      </td>",
"      <td>",
"       24.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 wk 4 days",
"      </td>",
"      <td>",
"       14.7",
"      </td>",
"      <td>",
"       19.8",
"      </td>",
"      <td>",
"       24.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 wk 5 days",
"      </td>",
"      <td>",
"       15.4",
"      </td>",
"      <td>",
"       20.5",
"      </td>",
"      <td>",
"       25.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 wk 6 days",
"      </td>",
"      <td>",
"       16.0",
"      </td>",
"      <td>",
"       21.1",
"      </td>",
"      <td>",
"       26.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11 wk 0 days",
"      </td>",
"      <td>",
"       16.7",
"      </td>",
"      <td>",
"       21.8",
"      </td>",
"      <td>",
"       26.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11 wk 1 days",
"      </td>",
"      <td>",
"       7.3",
"      </td>",
"      <td>",
"       22.4",
"      </td>",
"      <td>",
"       27.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11 wk 2 days",
"      </td>",
"      <td>",
"       18.0",
"      </td>",
"      <td>",
"       23.1",
"      </td>",
"      <td>",
"       28.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11 wk 3 days",
"      </td>",
"      <td>",
"       18.7",
"      </td>",
"      <td>",
"       23.7",
"      </td>",
"      <td>",
"       28.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11 wk 4 days",
"      </td>",
"      <td>",
"       19.3",
"      </td>",
"      <td>",
"       24.4",
"      </td>",
"      <td>",
"       29.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11 wk 5 days",
"      </td>",
"      <td>",
"       20.0",
"      </td>",
"      <td>",
"       25.0",
"      </td>",
"      <td>",
"       30.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11 wk 6 days",
"      </td>",
"      <td>",
"       20.6",
"      </td>",
"      <td>",
"       25.7",
"      </td>",
"      <td>",
"       30.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12 wk 0 days",
"      </td>",
"      <td>",
"       21.3",
"      </td>",
"      <td>",
"       26.3",
"      </td>",
"      <td>",
"       31.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12 wk 1 days",
"      </td>",
"      <td>",
"       21.9",
"      </td>",
"      <td>",
"       27.0",
"      </td>",
"      <td>",
"       32.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12 wk 2 days",
"      </td>",
"      <td>",
"       22.6",
"      </td>",
"      <td>",
"       27.6",
"      </td>",
"      <td>",
"       32.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12 wk 3 days",
"      </td>",
"      <td>",
"       23.2",
"      </td>",
"      <td>",
"       28.3",
"      </td>",
"      <td>",
"       33.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12 wk 4 days",
"      </td>",
"      <td>",
"       23.9",
"      </td>",
"      <td>",
"       28.9",
"      </td>",
"      <td>",
"       34.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12 wk 5 days",
"      </td>",
"      <td>",
"       24.9",
"      </td>",
"      <td>",
"       29.6",
"      </td>",
"      <td>",
"       34.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12 wk 6 days",
"      </td>",
"      <td>",
"       25.2",
"      </td>",
"      <td>",
"       30.2",
"      </td>",
"      <td>",
"       35.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13 wk 0 days",
"      </td>",
"      <td>",
"       25.8",
"      </td>",
"      <td>",
"       30.9",
"      </td>",
"      <td>",
"       35.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13 wk 1 days",
"      </td>",
"      <td>",
"       26.5",
"      </td>",
"      <td>",
"       31.5",
"      </td>",
"      <td>",
"       36.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13 wk 2 days",
"      </td>",
"      <td>",
"       27.1",
"      </td>",
"      <td>",
"       32.2",
"      </td>",
"      <td>",
"       37.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13 wk 3 days",
"      </td>",
"      <td>",
"       27.8",
"      </td>",
"      <td>",
"       32.8",
"      </td>",
"      <td>",
"       37.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13 wk 4 days",
"      </td>",
"      <td>",
"       28.4",
"      </td>",
"      <td>",
"       33.5",
"      </td>",
"      <td>",
"       38.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13 wk 5 days",
"      </td>",
"      <td>",
"       29.4",
"      </td>",
"      <td>",
"       34.1",
"      </td>",
"      <td>",
"       39.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13 wk 6 days",
"      </td>",
"      <td>",
"       29.7",
"      </td>",
"      <td>",
"       34.8",
"      </td>",
"      <td>",
"       39.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       14 wk 0 days",
"      </td>",
"      <td>",
"       30.3",
"      </td>",
"      <td>",
"       35.4",
"      </td>",
"      <td>",
"       40.5",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Prediction of gestational age based on crown-chin length in normal fetuses. Crown-chin length is below the 2.5th percentile in anencephalic fetuses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Sepulveda, W, Sebire, NJ, Fung, TY, Pip, E, Nicolaides, KH. Crown-chin length in normal and anencephalic fetuses at 10 to 14 weeks' gestation. Am J Obstet Gynecol 1997; 176:852. Original Table #1. Copyright &copy;1997 with permission from Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27661=[""].join("\n");
var outline_f27_0_27661=null;
var title_f27_0_27662="Ice ball formation";
var content_f27_0_27662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endometrial cryoablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ice ball formation after two freezes (without probe).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27662=[""].join("\n");
var outline_f27_0_27662=null;
var title_f27_0_27663="Pavlik harness PI";
var content_f27_0_27663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pavlik harness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows a device called a \"Pavlik harness\" that doctors can use to treat developmental dysplasia of the hip in babies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_0_27663=[""].join("\n");
var outline_f27_0_27663=null;
